



Clinical trial results:

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium (MK-0822-018)

Summary

EudraCT number	2011-005514-10
Trial protocol	LT
Global end of trial date	01 February 2017

Results information

Result version number	v1 (current)
This version publication date	24 October 2018
First version publication date	24 October 2018

Trial information

Trial identification

Sponsor protocol code	0822-018
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00529373
WHO universal trial number (UTN)	-
Other trial identifiers	Secondary Id: 2007_610, Registry Identifier: 132238, 2007-002693-66 : EudraCT

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 February 2017
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	01 February 2017
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The purpose of the event-driven base study is to determine the safety and efficacy, especially fracture risk reduction, of odanacatib in postmenopausal women diagnosed with osteoporosis. In a placebo-controlled extension of the base study, participants continued to receive the same blinded study medication for a total of up to 5 years of blinded study medication combined between the base study and the extension. After participants received 5 years of blinded study medication, they received open-label odanacatib through the end of the first extension. Participants were then invited to enroll in a second extension study in which they received open-label odanacatib for an additional 5 years. Two imaging substudies (PN032-Base/Extension and PN035) were conducted for participants in the MK-0822-018 Study. Additional safety information was collected for participants who discontinued from the base study or the blinded first extension in a separate observational follow-up study, MK-0822-083.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy:

Participants received standard-of-care therapy with Vitamin D3 (oral tablet; 5600 IU orally once weekly [OW]) and calcium carbonate (oral tablet; total daily calcium intake approximately 1200 mg but not to exceed 1600 mg) dietary supplements.

Evidence for comparator: -

Actual start date of recruitment	12 September 2007
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy, Regulatory reason
Long term follow-up duration	10 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 280
Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	Belgium: 37
Country: Number of subjects enrolled	Brazil: 1611
Country: Number of subjects enrolled	Bulgaria: 220
Country: Number of subjects enrolled	Chile: 62
Country: Number of subjects enrolled	China: 610
Country: Number of subjects enrolled	Colombia: 1999
Country: Number of subjects enrolled	Croatia: 33
Country: Number of subjects enrolled	Czech Republic: 317

Country: Number of subjects enrolled	Denmark: 1048
Country: Number of subjects enrolled	Dominican Republic: 144
Country: Number of subjects enrolled	Estonia: 170
Country: Number of subjects enrolled	France: 42
Country: Number of subjects enrolled	Germany: 27
Country: Number of subjects enrolled	Guatemala: 293
Country: Number of subjects enrolled	Hong Kong: 211
Country: Number of subjects enrolled	India: 981
Country: Number of subjects enrolled	Italy: 79
Country: Number of subjects enrolled	Japan: 454
Country: Number of subjects enrolled	Korea, Republic of: 194
Country: Number of subjects enrolled	Latvia: 53
Country: Number of subjects enrolled	Lebanon: 19
Country: Number of subjects enrolled	Lithuania: 178
Country: Number of subjects enrolled	Mexico: 421
Country: Number of subjects enrolled	New Zealand: 86
Country: Number of subjects enrolled	Norway: 289
Country: Number of subjects enrolled	Peru: 603
Country: Number of subjects enrolled	Philippines: 116
Country: Number of subjects enrolled	Poland: 1171
Country: Number of subjects enrolled	Romania: 129
Country: Number of subjects enrolled	Russian Federation: 793
Country: Number of subjects enrolled	Serbia: 60
Country: Number of subjects enrolled	South Africa: 1129
Country: Number of subjects enrolled	Spain: 61
Country: Number of subjects enrolled	Switzerland: 27
Country: Number of subjects enrolled	Taiwan: 64
Country: Number of subjects enrolled	Ukraine: 84
Country: Number of subjects enrolled	United Kingdom: 1711
Country: Number of subjects enrolled	United States: 262
Worldwide total number of subjects	16071
EEA total number of subjects	5565

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	12
From 65 to 84 years	15650
85 years and over	409

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Additional screening criteria applied.

Period 1

Period 1 title	Base Study
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Odanacatib 50 mg OW

Arm description:

Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Arm type	Experimental
Investigational medicinal product name	Odanacatib
Investigational medicinal product code	
Other name	MK-0822
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Arm title	Placebo
------------------	---------

Arm description:

Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Arm type	Placebo
Investigational medicinal product name	Placebo for Odanacatib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Number of subjects in period 1	Odanacatib 50 mg OW	Placebo
Started	8043	8028
Completed	6092	6198
Not completed	1951	1830
Adverse event, serious fatal	269	241
Physician decision	60	52
Consent withdrawn by subject	1062	967
Adverse event, non-fatal	256	229
Other Protocol Specified Criteria	19	20
Lost to follow-up	221	208
Lack of efficacy	16	75
Protocol deviation	48	38

Period 2

Period 2 title	Transition to First Extension Study
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Odanacatib 50 mg OW

Arm description:

Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Arm type	Experimental
Investigational medicinal product name	Odanacatib
Investigational medicinal product code	
Other name	MK-0822
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Arm title	Placebo
------------------	---------

Arm description:

Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo for Odanacatib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
50 mg tablet orally OW	

Number of subjects in period 2	Odanacatib 50 mg OW	Placebo
Started	6092	6198
Completed	4297	3960
Not completed	1795	2238
Did not continue into first extension	1795	2238

Period 3

Period 3 title	First Extension Double Blind Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Odanacatib 50 mg OW

Arm description:

Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Arm type	Experimental
Investigational medicinal product name	Odanacatib
Investigational medicinal product code	
Other name	MK-0822
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Arm title	Placebo
-----------	---------

Arm description:

Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Odanacatib
Investigational medicinal product code	
Other name	MK-0822
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Number of subjects in period 3	Odanacatib 50 mg OW	Placebo
Started	4297	3960
Completed	3640	2961
Not completed	657	999
Adverse event, serious fatal	109	86
Physician decision	50	45
Consent withdrawn by subject	296	287
Adverse event, non-fatal	53	56
Missing disposition	-	1
Other Protocol Specified Criteria	27	47
Lost to follow-up	41	37
Lack of efficacy	65	427
Protocol deviation	16	13

Period 4

Period 4 title	First Extension Open Label Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Odanacatib 50 mg OW

Arm description:

Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Arm type	Experimental
Investigational medicinal product name	Odanacatib
Investigational medicinal product code	
Other name	MK-0822
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Arm title	Odanacatib 50 mg OW (originally assigned to placebo)
------------------	--

Arm description:

Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Arm type	Experimental
Investigational medicinal product name	Odanacatib
Investigational medicinal product code	
Other name	MK-0822
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Number of subjects in period 4	Odanacatib 50 mg OW	Odanacatib 50 mg OW (originally assigned to placebo)
Started	3640	2961
Completed	3432	2615
Not completed	208	346
Physician decision	11	9
Consent withdrawn by subject	71	49
Adverse event, non-fatal	55	37
Missing disposition	2	5
Other Protocol Specified Criteria	20	14
Lost to follow-up	11	22
Lack of efficacy	36	205
Protocol deviation	2	5

Period 5

Period 5 title	Transition to Second Extension
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Odanacatib 50 mg OW
Arm description: Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.	
Arm type	Experimental
Investigational medicinal product name	Odanacatib
Investigational medicinal product code	
Other name	MK-0822
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Arm title	Odanacatib 50 mg OW (originally assigned to placebo)
Arm description: Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.	
Arm type	Experimental
Investigational medicinal product name	Placebo for Odanacatib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Number of subjects in period 5	Odanacatib 50 mg OW	Odanacatib 50 mg OW (originally assigned to placebo)
Started	3432	2615
Completed	3144	2309
Not completed	288	306
Did not continue into second extension	288	306

Period 6

Period 6 title	Second Extension Study
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Odanacatib 50 mg OW
Arm description:	
Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.	
Arm type	Experimental
Investigational medicinal product name	Odanacatib
Investigational medicinal product code	
Other name	MK-0822
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Arm title	Odanacatib 50 mg OW (originally assigned to placebo)
Arm description:	
Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.	
Arm type	Experimental
Investigational medicinal product name	Placebo for Odanacatib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg tablet orally OW

Number of subjects in period 6	Odanacatib 50 mg OW	Odanacatib 50 mg OW (originally assigned to placebo)
Started	3144	2309
Completed	2844	2112
Not completed	300	197
Adverse event, serious fatal	86	39
Physician decision	63	26
Consent withdrawn by subject	97	75
Adverse event, non-fatal	15	12
Missing disposition	5	5
Other Protocol Specified Criteria	7	12
Lost to follow-up	18	12
Lack of efficacy	7	15
Protocol deviation	2	1

Baseline characteristics

Reporting groups

Reporting group title	Odanacatib 50 mg OW
Reporting group description:	
Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.	
Reporting group title	Placebo
Reporting group description:	
Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.	

Reporting group values	Odanacatib 50 mg OW	Placebo	Total
Number of subjects	8043	8028	16071
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	6	6	12
From 65-84 years	7826	7824	15650
85 years and over	211	198	409
Age Continuous			
Units: years			
arithmetic mean	72.8	72.9	
standard deviation	± 5.4	± 5.3	-
Sex: Female, Male			
sxsss			
Units: Subjects			
Female	8043	8028	16071
Male	0	0	0
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	97	88	185
Asian	1421	1411	2832
Native Hawaiian or Other Pacific Islander	1	1	2
Black or African American	129	132	261
White	4528	4557	9085
More than one race	1867	1839	3706
Unknown or Not Reported	0	0	0
Stratum			

Units: Subjects			
Prior Vertebral Fracture	3733	3737	7470
No Prior Vertebral Fracture	4310	4291	8601
Bisphosphonate-Intolerant			
Units: Subjects			
Yes-	1423	1447	2870
No-	6615	6574	13189
Data N/A	5	7	12

Reporting group description:

Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly.

Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Reporting group title	Odanacatib 50 mg OW
-----------------------	---------------------

Reporting group description:

Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly. Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Reporting group title	Odanacatib 50 mg OW (originally assigned to placebo)
-----------------------	--

Reporting group description:

Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly.

Participants also receive 5600 IU Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Primary: Base Study: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture

End point title	Base Study: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture
-----------------	--

End point description:

Morphometric vertebral fractures were assessed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline and at Months 6, 12, and subsequent yearly time points. Incident fractures occurring after baseline were confirmed by quantitative morphometric (QM) and either SQ or binary SQ methodologies. A time-to-event methodology was used: life-table estimates of the proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and at yearly intervals; an interval-censored approach was used to determine incidence rate (number of participants with a morphometric fracture per 100 patient-years of follow-up). The Full-Analysis-Set (FAS) including all randomized participants, who took at least one dose of study medication with follow-up from start of prime therapy to study termination (base study) with at least one spine radiograph on treatment (and at baseline) was used.

End point type	Primary
----------------	---------

End point timeframe:

Up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6770	6910		
Units: Part.with fracture per 100 patient-years				
number (not applicable)	1.27	2.74		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW vs Placebo.
-----------------------------------	---------------------------------

Statistical analysis description:

Generalized linear model for binary data with cloglog link and terms for time interval, treatment, stratum, and geographic region. cloglog link = complementary log log transformation of probability of an

event up to the time-point.

Comparison groups	Placebo v Odanacatib 50 mg OW
Number of subjects included in analysis	13680
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Generalized linear model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	0.53

Primary: Base Study: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated)

End point title	Base Study: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated)
-----------------	--

End point description:

Osteoporotic clinical hip fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Hip fractures were fractures of the proximal femur confirmed as being located in the hip (i.e., sub-region not specified; cervical, and intertrochanteric). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 patient-years of follow-up) is provided. The FAS including all randomized participants who took at least one dose of study medication with follow-up from start of prime therapy to study termination (base study) was used for analysis.

End point type	Primary
----------------	---------

End point timeframe:

Up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part.with fracture per 100 patient-years				
number (not applicable)	0.28	0.54		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW vs Placebo.
-----------------------------------	---------------------------------

Statistical analysis description:

The Cox proportional hazards model included terms for treatment, stratum and geographic region.

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.39
upper limit	0.71

Primary: Base Study: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated)

End point title	Base Study: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated)
End point description:	Osteoporotic non-vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excl. fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anat. sites including clavicle, distal femur or shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (# of participants with a fracture per 100 patient-years of follow-up) is provided. The FAS including all rand. participants who took at least one dose of study medication with follow-up from start of prime therapy to study termination (base study) was used for analysis.
End point type	Primary
End point timeframe:	Up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part.with fracture per 100 patient-years				
number (not applicable)	1.85	2.41		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW vs Placebo.
Statistical analysis description:	The Cox proportional hazards model included terms for treatment, stratum and geographic region.
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	0.87

Primary: Base Study + First Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture

End point title	Base Study + First Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture
-----------------	--

End point description:

Morphometric vertebral fractures were assessed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline and at Months 6, 12, and subsequent yearly time points. Incident fractures occurring after baseline were confirmed by quantitative morphometric (QM) and either SQ or binary SQ methodologies. A time-to-event methodology was used: life-table estimates of the proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and at yearly intervals; an interval-censored approach was used to determine incidence rate (number of participants with a morphometric fracture per 100 patient-years of follow-up). The Full-Analysis-Set (FAS) including all randomized participants, who took at least one dose of study medication with follow-up from start of prime therapy to study termination (base study) with at least one spine radiograph on treatment (and at baseline) was used.

End point type	Primary
----------------	---------

End point timeframe:

Up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6909	7011		
Units: Part.with fracture per 100 patient-years				
number (not applicable)	1.33	2.74		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW vs Placebo.
----------------------------	---------------------------------

Statistical analysis description:

Generalized linear model for binary data with cloglog link and terms for time interval, treatment, stratum, and geographic region. cloglog link = complementary log log transformation of probability of an event up to the time-point.

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	13920
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Generalized linear model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.42
upper limit	0.55

Primary: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated)

End point title	Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated)
-----------------	--

End point description:

Osteoporotic clinical hip fractures was confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Hip fractures were fractures of the proximal femur confirmed as being located in the hip (i.e., sub-region not specified; cervical, and intertrochanteric). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 patient-years of follow-up) is provided.

End point type	Primary
----------------	---------

End point timeframe:

Up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part.with fracture per 100 patient-years				
number (not applicable)	0.29	0.56		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW vs Placebo.
----------------------------	---------------------------------

Statistical analysis description:

The Cox proportional hazards model included terms for treatment, stratum and geographic region.

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	0.67

Primary: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated)

End point title	Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated)
-----------------	--

End point description:

Osteoporotic non-vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur and shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 patient-years of follow-up) is provided.

End point type	Primary
----------------	---------

End point timeframe:

Up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part.with fracture per 100 patient-years				
number (not applicable)	1.78	2.41		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW vs Placebo.
----------------------------	---------------------------------

Statistical analysis description:

The Cox proportional hazards model included terms for treatment, stratum and geographic region.

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	0.83

Primary: Base Study + First Extension + Second Extension: Percent Change From Baseline in Bone Mineral Density (BMD) Measurements of the Total Hip

End point title	Base Study + First Extension + Second Extension: Percent Change From Baseline in Bone Mineral Density (BMD) Measurements of the Total Hip ^[1]
-----------------	--

End point description:

BMD was measured by dual-energy x-ray absorptiometry (DXA) at the total hip starting at screening & at yearly intervals until the end of study (second ext. study) for all participants who entered the second ext. study. Least squares (LS) means percent change in BMD from orig. baseline are provided through Month 108 (Year 9). At Months 96 (Year 8) & 108 (Year 9), approx. 3% or fewer patients in each treatment group had BMD data, & results at those time points should be viewed with caution. NOTE: The mean percent change in BMD from baseline in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medic. in the base study. The FAS population incl. all rand. patients who took at least one dose of study medication & with necessary on-treatment info. (total hip BMD) was used for analysis (base study + first ext-dbp + second ext).

End point type	Primary
----------------	---------

End point timeframe:

Baseline and once yearly up to 10 years

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No between-group statistical comparisons were performed for this endpoint.

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2997	2212		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 12 (n=2997, 2212)	3.03 (2.91 to 3.14)	1.08 (0.95 to 1.22)		
Month 24 (n=2965, 2189)	4.32 (4.18 to 4.46)	0.58 (0.42 to 0.74)		
Month 36 (n=2950, 2171)	5.60 (5.43 to 5.77)	0.04 (-0.16 to 0.24)		
Month 48 (n=2905, 2133)	6.56 (6.36 to 6.76)	-0.74 (-0.97 to -0.51)		
Month 60 (n=2718, 2015)	7.45 (7.22 to 7.68)	-1.40 (-1.67 to -1.13)		

Month 72 (n=2186, 1637)	7.88 (7.62 to 8.14)	-0.01 (-0.31 to 0.30)		
Month 84 (n=1631, 1197)	7.94 (7.63 to 8.26)	0.97 (0.61 to 1.34)		
Month 96 (n=237, 187)	7.87 (7.38 to 8.37)	1.57 (1.01 to 2.13)		
Month 108 (n=63, 51)	7.03 (6.02 to 8.05)	1.11 (-0.02 to 2.23)		

Statistical analyses

No statistical analyses for this end point

Primary: Imaging Substudy PN032-Base: Percent Change From Baseline in Volumetric Bone Mineral Density (vBMD) at the Lumbar Spine Using Quantitative Computed Tomography

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in Volumetric Bone Mineral Density (vBMD) at the Lumbar Spine Using Quantitative Computed Tomography
-----------------	--

End point description:

Compartment-specific effects of osteoporosis were assessed by measuring trabecular vBMD at the lumbar spine (L1 total vertebral body) using quantitative computed tomography. The percent change from baseline at Month 24 (base study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture [yes/no]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (lumbar spine vBMD) was used for analysis (PN032-Base).

End point type	Primary
----------------	---------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	46	48		
Units: mg/cm ³				
least squares mean (confidence interval 95%)	8.05 (4.48 to 11.62)	-0.87 (-4.37 to 2.64)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg vs Placebo
----------------------------	-----------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	8.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.9
upper limit	13.93

Primary: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in vBMD at the Lumbar Spine Using Quantitative Computed Tomography

End point title	Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in vBMD at the Lumbar Spine Using Quantitative Computed Tomography
-----------------	--

End point description:

Compartment-specific effects of osteoporosis were assessed by measuring trabecular vBMD at the lumbar spine (L1 total vertebral body) using quantitative computed tomography. The percent change from baseline at Month 60 (base study + extension study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture [yes/no]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (lumbar spine vBMD) was used for analysis (PN032-Base + Extension).

End point type	Primary
----------------	---------

End point timeframe:

Baseline, Month 60

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	25		
Units: mg/cm ³				
least squares mean (confidence interval 95%)	14.76 (7.68 to 21.83)	-11.69 (-18.69 to -4.69)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg vs Placebo
----------------------------	-----------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum (prior vertebral fracture (yes/no)) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	53
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	26.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	16.49
upper limit	36.4

Primary: Sarcopenia Substudy PN035: Change from Baseline in Appendicular Lean Body Mass (aLBM)

End point title	Sarcopenia Substudy PN035: Change from Baseline in Appendicular Lean Body Mass (aLBM)
-----------------	---

End point description:

Sarcopenia is the age-related loss of skeletal muscle mass and associated loss of strength. Progression of sarcopenia was assessed using aLBM as measured by total body DXA. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS for change from baseline at specific time-points including all randomized participants who took at least one dose of study medication and had the necessary baseline and on-treatment measurements available (aLBM) was used for analysis (PN035).

End point type	Primary
----------------	---------

End point timeframe:

Baseline and once yearly up to 4 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	257		
Units: kg				
least squares mean (confidence interval 95%)				
Month 12 (n=247, 257)	-0.20 (-0.28 to -0.12)	-0.18 (-0.26 to -0.10)		
Month 24 (n=239, 236)	-0.19 (-0.28 to -0.10)	-0.19 (-0.28 to -0.10)		
Month 36 (n=201, 187)	-0.36 (-0.45 to -0.27)	-0.32 (-0.41 to -0.23)		
Month 48 (n=36, 32)	-0.44 (-0.64 to -0.24)	-0.23 (-0.44 to -0.02)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.14
upper limit	0.09

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.12
upper limit	0.12

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-0.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.17
upper limit	0.09

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
Statistical analysis description: Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	0.08

Primary: Sarcopenia Substudy PN035: Change from Baseline in Short Physical Performance Battery (SPPB) Score

End point title	Sarcopenia Substudy PN035: Change from Baseline in Short Physical Performance Battery (SPPB) Score
End point description: The SPPB is used to assess physical function in older persons. The SPPB consists of 3 types of physical activities: standing balance, gait speed, and chair rise. Component activities are timed and then reduced to a categorical 0 to 4 scale based on time achieved. A higher composite score (range 0 to 12) indicates an improved function level. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS for change from baseline at specific time-points including all randomized participants who took at least one dose of study medication and had the necessary baseline and on-treatment measurements available (SPPB) was used for analysis (PN035).	
End point type	Primary
End point timeframe: Baseline and once yearly up to 4 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	251	253		
Units: Score on a scale				
least squares mean (confidence interval 95%)				
Month 12 (n=251, 253)	0.03 (-0.16 to 0.22)	-0.08 (-0.27 to 0.11)		
Month 24 (n=248, 235)	-0.04 (-0.25 to 0.16)	-0.19 (-0.40 to 0.02)		
Month 36 (n=230, 221)	-0.18 (-0.42 to 0.06)	-0.37 (-0.62 to -0.13)		

Month 48 (n=136, 111)	-0.05 (-0.34 to 0.24)	-0.24 (-0.55 to 0.07)		
-----------------------	-----------------------	-----------------------	--	--

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.16
upper limit	0.38

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.15
upper limit	0.44

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.15
upper limit	0.54

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.15
upper limit	0.54

Primary: Sarcopenia Substudy PN035: Percent Change from Baseline in Gait Speed	
End point title	Sarcopenia Substudy PN035: Percent Change from Baseline in Gait Speed
End point description:	
Gait speed is a component of the SPPB. Participants are asked to walk a distance of 4 meters at their normal pace. The test is performed 2 times, and the walk done in the shortest time is used for scoring. The activity is timed and then reduced to a categorical 0 to 4 scale based on time achieved. Higher scores indicate an improved function level. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS for change from baseline at specific time-points including all randomized participants who took at least one dose of study medication and had the necessary baseline and on-treatment measurements available (gait speed) was used for analysis (PN035).	
End point type	Primary
End point timeframe:	
Baseline and once yearly up to 4 years.	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	249	252		
Units: Score on a scale				
least squares mean (confidence interval 95%)				
Month 12 (n=249, 252)	-0.02 (-0.10 to 0.06)	-0.06 (-0.14 to 0.02)		
Month 24 (n=245, 233)	-0.02 (-0.11 to 0.07)	-0.10 (-0.19 to -0.00)		
Month 36 (n=227, 218)	-0.09 (-0.19 to 0.02)	-0.11 (-0.22 to -0.01)		
Month 48 (n=135, 111)	-0.15 (-0.28 to -0.02)	-0.24 (-0.38 to -0.10)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	501
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.08
upper limit	0.15

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	501
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	0.21

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	501
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.12
upper limit	0.17

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	501
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.09
upper limit	0.28

Primary: Base study: Rate of Adverse Events

End point title	Base study: Rate of Adverse Events
End point description:	
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participants with adverse events (number of participants with an event per 100 patient-years of follow-up) is provided. The All-Participants-as-Treated population including all randomized patients who took at least one dose of study medication was used for analysis (base study).	
End point type	Primary
End point timeframe:	
Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (confidence interval 95%)	100.16 (97.81 to 102.6)	98.65 (96.33 to 101.01)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	
Miettinen & Nurminen method based 95% confidence interval	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in rates
Point estimate	1.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	4.84

Primary: Base Study: Rate of Discontinuation from Study Treatment Due to an AE

End point title	Base Study: Rate of Discontinuation from Study Treatment Due to an AE
End point description:	
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participant discontinuations from treatment due to adverse events (number of participants with an event per 100 patient-years of follow-up) is provided. The All-Participants-as-Treated population including all randomized patients who took at least one dose of study medication was used for analysis (base study).	
End point type	Primary
End point timeframe:	
Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (confidence interval 95%)	2.97 (2.75 to 3.20)	2.70 (2.49 to 2.92)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	
Miettinen & Nurminen method based 95% confidence interval	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in rates
Point estimate	0.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.04
upper limit	0.58

Primary: Base Study: Time to First 3-Point Major Adverse Cardiac Event (MACE) Confirmed by Thrombolysis in Myocardial Infarction Study Group (TIMI) Adjudication

End point title	Base Study: Time to First 3-Point Major Adverse Cardiac Event (MACE) Confirmed by Thrombolysis in Myocardial Infarction Study Group (TIMI) Adjudication
End point description:	
<p>The time to first TIMI-adjudicated 3-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, or 3. non-fatal definite stroke) was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).</p>	
End point type	Primary
End point timeframe:	
Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	1.17	1.04		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description: Cox proportional hazards model with terms for treatment, stratum and geographic region.	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.182
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.95
upper limit	1.34

Primary: Base Study: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication

End point title	Base Study: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
End point description: The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).	
End point type	Primary
End point timeframe: Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.48	0.41		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	
Cox proportional hazards model with terms for treatment, stratum and geographic region	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.235
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	1.55

Primary: Base study + First Extension: Rate of Adverse Events

End point title	Base study + First Extension: Rate of Adverse Events
End point description:	
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participants with adverse events (number of participants with an event per 100 patient-years of follow-up) is provided. The All-Participants-as-Treated population including all randomized patients who took at least one dose of study medication was used for analysis (base study + first extension).	
End point type	Primary
End point timeframe:	
Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (confidence interval 95%)	97.25 (95.00 to 99.53)	96.36 (94.13 to 98.63)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	
Miettinen & Nurminen method based 95% Confidence Interval	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in rates
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	4.07

Primary: Base Study + First Extension: Rate of Discontinuation from Study Treatment Due to an AE

End point title	Base Study + First Extension: Rate of Discontinuation from Study Treatment Due to an AE
End point description:	
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participant discontinuations from treatment due to adverse events (number of participants with an event per 100 patient-years of follow-up) is provided. The All-Participants-as-Treated population including all randomized patients who took at least one dose of study medication was used for analysis (base study + first extension).	
End point type	Primary
End point timeframe:	
Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (confidence interval 95%)	2.66 (2.48 to 2.86)	2.55 (2.37 to 2.75)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	
Miettinen & Nurminen method based 95% Confidence Interval	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in rates
Point estimate	0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.16
upper limit	0.37

Primary: Base Study + First Extension: Time to First 3-Point MACE Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First 3-Point MACE Confirmed by TIMI Adjudication
End point description:	
<p>The time to first TIMI-adjudicated 3-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, or 3. non-fatal definite stroke) was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).</p>	
End point type	Primary
End point timeframe:	
Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	1.24	1.06		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	
Cox proportional hazards model with terms for treatment, stratum and geographic region	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.029
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.02
upper limit	1.36

Primary: Base Study + First Extension: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
End point description:	
<p>The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).</p>	
End point type	Primary
End point timeframe:	
Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.51	0.43		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	
Cox proportional hazards model with terms for treatment, stratum and geographic region	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.178
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.93
upper limit	1.46

Primary: Second Extension: Number of Participants who Experienced an Adverse Event

End point title	Second Extension: Number of Participants who Experienced an Adverse Event ^[2]
End point description:	
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The All-Participants-as-Treated population including all patients who took at least one dose of study medication was used for analysis (second extension study).	
End point type	Primary
End point timeframe:	
Up to 5 years (in the second extension)	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No between-group statistical comparisons were performed for this endpoint.

End point values	Odanacatib 50 mg OW	Odanacatib 50 mg OW (originally assigned to placebo)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3144	2309		
Units: Participants	2173	1587		

Statistical analyses

No statistical analyses for this end point

Primary: Second Extension: Number of Participants Discontinuing Study Treatment Due to an AE

End point title	Second Extension: Number of Participants Discontinuing Study Treatment Due to an AE ^[3]
-----------------	--

End point description:

An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The All-Participants-as-Treated population including all patients who took at least one dose of study medication was used for analysis (second extension).

End point type	Primary
----------------	---------

End point timeframe:

Up to 5 years (in the second extension)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No between-group statistical comparisons were performed for this endpoint.

End point values	Odanacatib 50 mg OW	Odanacatib 50 mg OW (originally assigned to placebo)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3144	2309		
Units: Participants	55	36		

Statistical analyses

No statistical analyses for this end point

Secondary: Base Study: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated)

End point title	Base Study: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated)
-----------------	--

End point description:

Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological

etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 patient-years of follow-up) is provided. The FAS including all randomized participants who took at least one dose of study medication with follow-up from start of prime therapy to study termination (base study) was used for analysis.

End point type	Secondary
End point timeframe:	
Up to 5 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part.with fracture per 100 patient-years				
number (not applicable)	0.16	0.58		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW vs Placebo.
Statistical analysis description:	
The Cox proportional hazards model included terms for treatment, stratum and geographic region.	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	0.4

Secondary: Base Study: Yearly Rate of Height Loss

End point title	Base Study: Yearly Rate of Height Loss
End point description:	
Height was measured by wall-mounted stadiometer at randomization and at yearly intervals in the base study. The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (height) was used for analysis (base study).	
End point type	Secondary
End point timeframe:	
Baseline and once yearly up to 5 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6112	6231		
Units: cm/year				
least squares mean (confidence interval 95%)	-0.13 (-0.14 to -0.12)	-0.15 (-0.16 to -0.14)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW versus Placebo.
Statistical analysis description:	
The mixed model contained fixed effects for treatment, region, stratum, treatment-year interaction and random effect intercept and slope (year) and unstructured covariance matrix.	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12343
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.041
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0.03

Secondary: Base Study: Number of Participants with Height Loss of > 1 cm

End point title	Base Study: Number of Participants with Height Loss of > 1 cm
End point description:	
Height was measured by wall-mounted stadiometer at randomization and at yearly intervals in the base study. The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (height loss) was used for analysis (base study).	
End point type	Secondary
End point timeframe:	
Baseline and once yearly up to 5 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6095	6215		
Units: Participants				
Up to Month 12 (n=6095, 6215)	316	365		
Up to Month 24 (n=5347, 5396)	592	669		
Up to Month 36 (n=4745, 4632)	875	944		
Up to Month 48 (n=331, 281)	90	59		
Up to Month 60 (n=103, 70)	23	12		
Overall/At any time (n=6095, 6215)	1022	1149		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW versus Placebo.
Statistical analysis description:	
Treatment comparison for height loss at any time during the treatment period. The logistic model contained terms for treatment, geographic region and stratum.	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12310
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.014
Method	Logistic model
Parameter estimate	Odds ratio (OR)
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	0.98

Secondary: Base Study: Percent Change from Baseline in BMD Measurements of the Total Hip

End point title	Base Study: Percent Change from Baseline in BMD Measurements of the Total Hip
End point description:	
BMD was measured by DXA for all participants at the total hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study). The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (total hip BMD) was used for analysis (base study).	
End point type	Secondary
End point timeframe:	
Baseline, Month 6, and once yearly up to 5 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6490	6596		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 6 (n=292, 302)	1.85 (1.54 to 2.16)	0.53 (0.24 to 0.81)		
Month 12 (n=6490, 6596)	2.82 (2.74 to 2.91)	0.33 (0.25 to 0.42)		
Month 24 (n=5916, 5895)	3.79 (3.68 to 3.90)	-0.68 (-0.79 to -0.57)		
Month 36 (n=5127, 4925)	4.81 (4.67 to 4.94)	-1.64 (-1.78 to -1.50)		
Month 48 (n=539, 452)	5.39 (5.04 to 5.74)	-3.23 (-3.59 to -2.87)		
Month 60 (n=167, 138)	5.67 (5.13 to 6.21)	-3.82 (-4.40 to -3.24)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	1.75

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.37
upper limit	2.61

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	4.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.31
upper limit	4.62

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	6.44

Confidence interval	
level	95 %
sides	2-sided
lower limit	6.25
upper limit	6.64

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	8.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.11
upper limit	9.12

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	9.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.7
upper limit	10.29

Secondary: Base Study: Percent Change from Baseline in BMD Measurements of the Lumbar Spine

End point title	Base Study: Percent Change from Baseline in BMD
-----------------	---

End point description:

BMD was measured by DXA for all participants at the lumbar spine at randomization, Months 6, 12, and subsequent yearly intervals until the end of the study (base study). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (lumbar spine BMD) was used for analysis (base study).

End point type

Secondary

End point timeframe:

Baseline, Month 6, and once yearly up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6344	6400		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 6 (n=293, 299)	3.75 (3.39 to 4.11)	0.78 (0.44 to 1.13)		
Month 12 (n=6344, 6400)	4.67 (4.56 to 4.77)	0.59 (0.49 to 0.70)		
Month 24 (n=5805, 5778)	6.77 (6.64 to 6.90)	0.72 (0.59 to 0.84)		
Month 36 (n=5086, 4913)	8.59 (8.43 to 8.74)	0.75 (0.59 to 0.90)		
Month 48 (n=503, 441)	10.47 (10.09 to 10.86)	0.76 (0.35 to 1.16)		
Month 60 (n=169, 138)	11.49 (10.82 to 12.17)	0.26 (-0.47 to 1.00)		

Statistical analyses

Statistical analysis title

Odanacatib 50 mg OW - Placebo at Month 6.

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12744
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.47
upper limit	3.46

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12744
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	4.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.93
upper limit	4.22

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12744
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	6.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.87
upper limit	6.23

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	12744
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	7.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.62
upper limit	8.06

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12744
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	9.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.16
upper limit	10.27

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12744
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	11.23

Confidence interval	
level	95 %
sides	2-sided
lower limit	10.23
upper limit	12.23

Secondary: Base Study: Percent Change from Baseline in BMD Measurements of the Femoral Neck

End point title	Base Study: Percent Change from Baseline in BMD Measurements of the Femoral Neck
End point description: BMD was measured by DXA for all participants at the femoral neck-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study). The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (femoral neck BMD) was used for analysis (base study).	
End point type	Secondary
End point timeframe: Baseline, Month 6, and once yearly up to 5 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6490	6597		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 6 (n=292, 302)	2.17 (1.78 to 2.55)	0.68 (0.30 to 1.06)		
Month 12 (n=6490, 6597)	2.80 (2.68 to 2.91)	0.59 (0.48 to 0.70)		
Month 24 (n=5916, 5895)	4.01 (3.88 to 4.15)	-0.37 (-0.50 to -0.23)		
Month 36 (n=5126, 4925)	5.45 (5.29 to 5.61)	-1.01 (-1.17 to -0.85)		
Month 48 (n=539, 452)	6.15 (5.74 to 6.56)	-2.27 (-2.71 to -1.83)		
Month 60 (n=167, 138)	6.69 (6.02 to 7.36)	-1.84 (-2.58 to -1.11)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	13087
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.95
upper limit	2.03

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13087
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.05
upper limit	2.37

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13087
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	4.38

Confidence interval	
level	95 %
sides	2-sided
lower limit	4.19
upper limit	4.57

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13087
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	6.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.24
upper limit	6.68

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13087
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	8.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.82
upper limit	9.02

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13087
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	8.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.54
upper limit	9.53

Secondary: Base Study: Percent Change from Baseline in BMD Measurements of the Trochanter

End point title	Base Study: Percent Change from Baseline in BMD Measurements of the Trochanter
-----------------	--

End point description:

BMD was measured by DXA for all participants at the trochanter-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study). The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (trochanter BMD) was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6490	6596		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 6 (n=292, 302)	2.65 (2.12 to 3.18)	0.91 (0.43 to 1.38)		
Month 12 (n=6490, 6596)	4.32 (4.18 to 4.46)	0.82 (0.68 to 0.96)		
Month 24 (n=5916, 5895)	6.17 (6.00 to 6.34)	-0.24 (-0.41 to -0.07)		
Month 36 (n=5127, 4925)	8.01 (7.81 to 8.22)	-1.26 (-1.47 to -1.05)		
Month 48 (n=539, 452)	9.46 (8.92 to 10.00)	-2.98 (-3.54 to -2.42)		
Month 60 (n=167, 138)	10.16 (9.32 to 10.99)	-3.65 (-4.55 to -2.75)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.03
upper limit	2.46

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.31
upper limit	3.7

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24
-----------------------------------	---

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment &

time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	6.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.17
upper limit	6.65

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36
-----------------------------------	---

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	9.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.98
upper limit	9.57

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48
-----------------------------------	---

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	12.44

Confidence interval	
level	95 %
sides	2-sided
lower limit	11.66
upper limit	13.22

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60
-----------------------------------	---

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13086
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	13.81

Confidence interval

level	95 %
sides	2-sided
lower limit	12.58
upper limit	15.04

Secondary: Base Study: Percent Change from Baseline in BMD Measurements of the Distal-Third Forearm

End point title	Base Study: Percent Change from Baseline in BMD Measurements of the Distal-Third Forearm
-----------------	--

End point description:

BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study) in an approximate 10% random subset of participants at selected sites. The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (distal one-third radius BMD) was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and once yearly up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	679	718		
Units: g/cm ²				
least squares mean (confidence interval 95%)				

Month 12 (n=679, 718)	0.51 (0.19 to 0.82)	-0.60 (-0.91 to -0.30)		
Month 24 (n=619, 635)	0.33 (-0.03 to 0.68)	-1.02 (-1.37 to -0.68)		
Month 36 (n=569, 558)	0.02 (-0.36 to 0.41)	-1.90 (-2.29 to -1.52)		
Month 48 (n=85, 77)	-0.62 (-1.52 to 0.28)	-2.82 (-3.76 to -1.88)		
Month 60 (n=32, 26)	0.29 (-1.08 to 1.66)	-3.21 (-4.72 to -1.70)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.67
upper limit	1.55

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.85
upper limit	1.84

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.38
upper limit	2.47

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.89
upper limit	3.51

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.46
upper limit	5.54

Secondary: Base Study: Percent Change From Baseline in BMD Measurements of the Lumbar Spine in Bisphosphonate-Intolerant Participants

End point title	Base Study: Percent Change From Baseline in BMD Measurements of the Lumbar Spine in Bisphosphonate-Intolerant Participants
-----------------	--

End point description:

BMD was measured by DXA in bisphosphonate-intolerant participants at the lumbar spine at randomization, and at yearly intervals until the end of the study (base study). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment. Timepoints with a minimum of 50% participant visits were included in the multiplicity adjustment strategy towards significance testing; therefore, timepoints with fewer participants than threshold were either not analyzed (i.e., Months 6, 60) or results should be viewed with caution as exploratory results (i.e., Month 48).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1116	1127		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 12 (n=1116, 1127)	4.56 (4.31 to 4.80)	0.54 (0.29 to 0.78)		
Month 24 (n=1025, 1004)	6.60 (6.31 to 6.90)	0.82 (0.52 to 1.11)		
Month 36 (n=889, 853)	8.49 (8.13 to 8.85)	0.87 (0.50 to 1.23)		
Month 48 (n=63, 40)	10.31 (9.34 to 11.29)	0.80 (-0.40 to 2.00)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2243
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	4.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.67
upper limit	4.37

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2243
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	5.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.37
upper limit	6.2

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	2243
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	7.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.11
upper limit	8.13

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2243
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	9.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.96
upper limit	11.06

Secondary: Base Study: Percent Change From Baseline in BMD Measurements of the Total Hip in Bisphosphonate-Intolerant Participants

End point title	Base Study: Percent Change From Baseline in BMD Measurements of the Total Hip in Bisphosphonate-Intolerant Participants
-----------------	---

End point description:

BMD was measured by DXA in bisphosphonate-intolerant participants at the total hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment. Timepoints with a minimum of 50% participant visits were included in the multiplicity adjustment strategy towards significance testing; therefore, timepoints with fewer participants than threshold were either not analyzed (i.e., Months 6, 60) or results should be viewed with caution as exploratory results (i.e., Month 48). The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (total hip BMD) was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 5 years

End point values	Odanacetib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1127	1155		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 12 (n=1127, 1155)	2.63 (2.43 to 2.83)	0.24 (0.04 to 0.44)		
Month 24 (n=1035, 1020)	3.56 (3.30 to 3.82)	-0.64 (-0.90 to -0.39)		
Month 36 (n=889, 853)	4.45 (4.14 to 4.76)	-1.41 (-1.72 to -1.09)		
Month 48 (n=65, 42)	4.07 (3.09 to 5.04)	-4.47 (-5.67 to -3.27)		

Statistical analyses

Statistical analysis title	Odanacetib 50 mg OW - Placebo at Month 12.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacetib 50 mg OW v Placebo
Number of subjects included in analysis	2282
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.11
upper limit	2.68

Statistical analysis title	Odanacetib 50 mg OW - Placebo at Month 24.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacetib 50 mg OW v Placebo

Number of subjects included in analysis	2282
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	4.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.84
upper limit	4.57

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2282
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	5.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.41
upper limit	6.3

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2282
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	8.54

Confidence interval	
level	95 %
sides	2-sided
lower limit	7
upper limit	10.09

Secondary: Base Study: Percent Change From Baseline in BMD Measurements of the Femoral Neck in Bisphosphonate-Intolerant Participants

End point title	Base Study: Percent Change From Baseline in BMD Measurements of the Femoral Neck in Bisphosphonate-Intolerant Participants
-----------------	--

End point description:

BMD was measured by DXA in bisphosphonate-intolerant participants at the femoral neck-hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment. Timepoints with a minimum of 50% participant visits were included in the multiplicity adjustment strategy towards significance testing; therefore, timepoints with fewer participants than threshold were either not analyzed (i.e., Months 6, 60) or results should be viewed with caution as exploratory results (i.e., Month 48). The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (femoral neck BMD) was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1127	1156		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 12 (n=1127, 1156)	2.71 (2.44 to 2.98)	0.50 (0.24 to 0.77)		
Month 24 (n=1035, 1020)	3.88 (3.56 to 4.19)	-0.45 (-0.77 to -0.13)		
Month 36 (n=889, 853)	5.12 (4.75 to 5.50)	-0.97 (-1.35 to -0.59)		
Month 48 (n=65, 42)	6.75 (5.43 to 8.08)	-2.32 (-3.96 to -0.68)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
----------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	2283
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.83
upper limit	2.59

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2283
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	4.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.87
upper limit	4.78

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2283
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	6.09

Confidence interval	
level	95 %
sides	2-sided
lower limit	5.56
upper limit	6.62

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2283
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	9.08

Confidence interval

level	95 %
sides	2-sided
lower limit	6.97
upper limit	11.19

Secondary: Base Study: Percent Change From Baseline in BMD Measurements of the Trochanter in Bisphosphonate-Intolerant Participants

End point title	Base Study: Percent Change From Baseline in BMD Measurements of the Trochanter in Bisphosphonate-Intolerant Participants
-----------------	--

End point description:

BMD was measured by DXA in bisphosphonate-intolerant participants at the trochanter-hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment. Timepoints with a minimum of 50% participant visits were included in the multiplicity adjustment strategy towards significance testing; therefore, timepoints with fewer participants than threshold were either not analyzed (i.e., Months 6, 60) or results should be viewed with caution as exploratory results (i.e., Month 48). The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (trochanter BMD) was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1127	1155		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 12 (n=1127, 1155)	4.02 (3.70 to 4.35)	0.58 (0.26 to 0.90)		
Month 24 (n=1035, 1020)	5.73 (5.33 to 6.12)	-0.30 (-0.70 to 0.10)		
Month 36 (n=889, 853)	7.47 (6.99 to 7.94)	-1.02 (-1.50 to -0.54)		
Month 48 (n=65, 42)	6.68 (5.04 to 8.32)	-5.07 (-7.09 to -3.05)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12
Statistical analysis description:	
The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2282
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	3.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.98
upper limit	3.9

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description:	
The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2282
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	6.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	5.47
upper limit	6.59

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2282
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	8.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.81
upper limit	9.16

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	2282
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	11.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.15
upper limit	14.36

Secondary: Base Study: Percent Change From Baseline in BMD Measurements of the Distal-Third Forearm in Bisphosphonate-Intolerant Participants

End point title	Base Study: Percent Change From Baseline in BMD
-----------------	---

End point description:

BMD was measured by DXA at the distal one-third radius at rand. and at yearly intervals until the end of study (base study) in an approx. 10% random subset of bisphosphonate-intolerant participants at selected sites. Bisphosphonates are anti-resorptive agents used in treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindic. or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment. Timepoints with a minimum of 50% participant visits were included in the multiplicity adjustment strategy towards signific. testing; therefore, timepoints with fewer participants than threshold were either not analyzed (i.e., Month 60) or results should be viewed with caution as explor. results (i.e., Month 48). The FAS population including all rand. patients who took at least one dose of study medication and having the necessary on-treatment information (distal one-third radius BMD) was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and once yearly up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	77	112		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 12 (n=77, 112)	0.99 (0.06 to 1.93)	-0.09 (-0.87 to 0.69)		
Month 24 (n=71, 100)	0.24 (-0.79 to 1.28)	-0.80 (-1.67 to 0.06)		
Month 36 (n=64, 82)	-0.66 (-1.76 to 0.44)	-1.87 (-2.82 to -0.92)		
Month 48 (n=8, 5)	-0.72 (-4.90 to 3.45)	-2.27 (-7.23 to 2.68)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
----------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	189
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.083
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.14
upper limit	2.31

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	189
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.129
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.31
upper limit	2.4

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	189
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.104
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.25
upper limit	2.67

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	189
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.617
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.92
upper limit	8.02

Secondary: Base Study: Percent Change From Baseline in Serum C-Telopeptides of Type I Collagen (s-CTx) After Log-Transformation

End point title	Base Study: Percent Change From Baseline in Serum C-Telopeptides of Type I Collagen (s-CTx) After Log-Transformation
-----------------	--

End point description:

s-CTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in s-CTx was determined using a longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided. The per-protocol population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (s-CTx) and excluding participants and/or data points that represent clinically important deviations from the protocol-specified criteria was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 4 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	618	629		
Units: ng/mL				
geometric mean (confidence interval 95%)				
Month 6 (n=571, 585)	-61.27 (-63.33 to -59.09)	-2.28 (-7.43 to 3.15)		
Month 12 (n=618, 629)	-53.47 (-55.98 to -50.81)	6.54 (0.85 to 12.56)		
Month 24 (n=528, 534)	-39.47 (-42.61 to -36.15)	7.23 (1.70 to 13.07)		
Month 36 (n=447, 414)	-23.71 (-27.79 to -19.40)	20.96 (14.38 to 27.91)		
Month 48 (n=55, 54)	-4.61 (-15.93 to 8.24)	14.12 (0.47 to 29.61)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
Statistical analysis description: Longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1247
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-58.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	-64.68
upper limit	-53.3

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description: Longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1247
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-60.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-66.4
upper limit	-53.61

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
-----------------------------------	--

Statistical analysis description:

Longitudinal model with terms for treatment, stratum, region and interaction between treatment and

time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1247
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-46.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-53.23
upper limit	-40.17

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

Longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1247
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-44.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	-52.62
upper limit	-36.72

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

Longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1247
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.05
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-18.73

Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.44
upper limit	-0.01

Secondary: Base Study: Percent Change From Baseline in Urinary N-Telopeptides of Type I Collagen/Creatinine (u-NTx/Cr) Ratio After Log-Transformation

End point title	Base Study: Percent Change From Baseline in Urinary N-Telopeptides of Type I Collagen/Creatinine (u-NTx/Cr) Ratio After Log-Transformation
-----------------	--

End point description:

u-NTx, a biochemical marker of bone resorption, was assessed at rand., Month 6, & at yearly intervals until end of study (base study) in an approx. 10% random subset participants at selected sites. Urine NTx measurements (in bone collagen equivalents [BCE]) were normalized to urine Cr concentration (i.e., u-NTx/Cr ratio) & the log-transformed fraction from baseline in u-NTx/Cr ratio was then determined using a longitudinal model with terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size). Back-transformed weighted geom. LS means values for percent change from baseline are provided. The per-protocol population incl. all rand. patients who took at least one dose of study medication and having the necessary on-treatment information (u-NTx/Cr) & excluding participants and/or data points that represent clinically important deviations from the protocol-specified criteria was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 4 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	603	619		
Units: nmol BCE/mmol				
geometric mean (confidence interval 95%)				
Month 6 (n=554, 569)	-56.46 (-58.27 to -54.56)	-4.76 (-8.68 to -0.67)		
Month 12 (n=603, 619)	-55.58 (-57.54 to -53.53)	-1.99 (-6.26 to 2.48)		
Month 24 (n=516, 516)	-47.21 (-49.70 to -44.61)	9.46 (4.33 to 14.85)		
Month 36 (n=438, 406)	-43.91 (-46.80 to -40.86)	15.23 (9.15 to 21.64)		
Month 48 (n=49, 52)	-38.01 (-46.30 to -28.43)	6.53 (-7.38 to 22.53)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
----------------------------	---

Statistical analysis description:

Longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1222
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-51.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-56.11
upper limit	-47.28

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
-----------------------------------	--

Statistical analysis description:

Longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1222
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-53.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	-58.39
upper limit	-48.79

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
-----------------------------------	--

Statistical analysis description:

Longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1222
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-56.68

Confidence interval	
level	95 %
sides	2-sided
lower limit	-62.52
upper limit	-50.84

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

Longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1222
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-59.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-66.04
upper limit	-52.23

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

Longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1222
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-44.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	-61.72
upper limit	-27.36

Secondary: Base Study: Percent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP) After Log-Transformation

End point title	Base Study: Percent Change From Baseline in Bone-Specific
-----------------	---

End point description:

BSAP is an enzyme produced by matrix-synthesizing osteoblasts during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum BSAP was assessed at rand., Month 6, and at yearly intervals until the end of the study (base study) in an approx. 10% random subset participants at selected sites. The log-transformed fraction from baseline in BSAP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided. The per-protocol population including all rand. patients who took at least one dose of study medication and having the necessary on-treatment information (BSAP) and excluding participants and/or data points that represent clinically important deviations from the protocol-specified criteria was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 4 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	634	650		
Units: ng/mL				
geometric mean (confidence interval 95%)				
Month 6 (n=594, 614)	-23.27 (-25.12 to -21.38)	-9.13 (-11.28 to -6.93)		
Month 12 (n=634, 650)	-21.43 (-23.53 to -19.27)	-9.42 (-11.80 to -6.97)		
Month 24 (n=543, 545)	-9.33 (-12.10 to -6.47)	-0.04 (-3.07 to 3.08)		
Month 36 (n=460, 433)	-8.41 (-11.23 to -5.51)	-0.77 (-3.85 to 2.40)		
Month 48 (n=59, 55)	-0.63 (-8.39 to 7.80)	0.15 (-7.93 to 8.94)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
----------------------------	---

Statistical analysis description:

Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-14.13

Confidence interval	
level	95 %
sides	2-sided
lower limit	-17
upper limit	-11.27

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
-----------------------------------	--

Statistical analysis description:

Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-12.01

Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.22
upper limit	-8.79

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
-----------------------------------	--

Statistical analysis description:

Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-9.29

Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.45
upper limit	-5.13

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-7.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.87
upper limit	-3.41

Statistical analysis title

Odanacatib 50 mg OW - Placebo at Month 48.

Statistical analysis description:

Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.896
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-0.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.34
upper limit	10.79

Secondary: Base Study: Percent Change From Baseline in N-Terminal Propeptide of Type 1 Collagen (P1NP) After Log-Transformation

End point title	Base Study: Percent Change From Baseline in N-Terminal Propeptide of Type 1 Collagen (P1NP) After Log-Transformation
-----------------	--

End point description:

P1NP is a cleavage fragment produced during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum P1NP was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in P1NP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided. The per-protocol population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (P1NP) and excluding participants and/or data points that represent clinically important deviations from the protocol-specified criteria was used for analysis (base study).

End point type	Secondary
End point timeframe:	
Baseline, Month 6, and once yearly up to 4 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	634	650		
Units: ng/mL				
geometric mean (confidence interval 95%)				
Month 6 (n=594, 613)	-44.51 (-46.71 to -42.23)	-15.08 (-18.39 to -11.65)		
Month 12 (n=634, 650)	-37.49 (-40.12 to -34.75)	-11.55 (-15.21 to -7.72)		
Month 24 (n=543, 545)	-22.46 (-25.69 to -19.09)	-6.20 (-10.08 to -2.16)		
Month 36 (n=460, 433)	-11.89 (-15.70 to -7.92)	0.22 (-4.15 to 4.78)		
Month 48 (n=59, 55)	-3.61 (-12.04 to 5.62)	-0.28 (-9.25 to 9.58)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-29.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.47
upper limit	-25.39

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description:	
Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal
Parameter estimate	Mean difference (final values)
Point estimate	-25.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	-30.54
upper limit	-21.34

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
-----------------------------------	--

Statistical analysis description:

Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal
Parameter estimate	Mean difference (final values)
Point estimate	-16.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.41
upper limit	-11.12

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal
Parameter estimate	Mean difference (final values)
Point estimate	-12.11

Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.03
upper limit	-6.19

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

Longitudinal model includes terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS Means weighted for region and stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1284
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.61
Method	Longitudinal
Parameter estimate	Mean difference (final values)
Point estimate	-3.34

Confidence interval

level	95 %
sides	2-sided
lower limit	-16.12
upper limit	9.45

Secondary: Base Study + First Extension + Second Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture

End point title	Base Study + First Extension + Second Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture
-----------------	---

End point description:

Morphometric vertebral fractures were assessed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline and at Months 6, 12, and subsequent yearly time points. Incident fractures occurring after baseline were confirmed by quantitative morphometric (QM) and either SQ or binary SQ methodologies. A time-to-event methodology was used: life-table estimates of the proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and at yearly intervals; an interval-censored approach was used to determine incidence rate (number of participants with a morphometric fracture per 100 patient-years of follow-up). The Full-Analysis-Set (FAS) including all randomized participants, who took at least one dose of study medication with follow-up from start of prime therapy to study termination (base study) with at least one spine radiograph on treatment (and at baseline) was used.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 10 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[4]	0 ^[5]		
Units: Part.with fracture per 100 patient-years				
number (not applicable)				

Notes:

[4] - The study was terminated early to an observed increase in risk of stroke in protocol 0822-018

[5] - The study was terminated early to an observed increase in risk of stroke in protocol 0822-018

Statistical analyses

No statistical analyses for this end point

Secondary: Second Extension: Incidence of Osteoporotic Clinical Thoracic Vertebral Fracture (Adjudicated)

End point title	Second Extension: Incidence of Osteoporotic Clinical Thoracic Vertebral Fracture (Adjudicated)
-----------------	--

End point description:

Osteoporotic vertebral clinical fractures were confirmed by central adjudic. using radiographic evidence on all symptomatic fractures reported as adverse experiences (excl. fractures of fingers, toes, face, & skull). Vertebral fractures were assessed for all thoracic vertebral levels (T1 to T12). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence of participants in the second ext. study with osteoporotic vertebral clinical fractures is provided. Due to early term. of the study, cumulative incidence using a time-to-event methodology was not assessed across base and ext. studies. The All-Participants-as-Treated Population including all rand. participants who entered the second ext. study & received at least one dose of open-label treatment was used for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (in the second extension)

End point values	Odanacatib 50 mg OW	Odanacatib 50 mg OW (originally assigned to placebo)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3144	2309		
Units: Percentage of Participants				
number (not applicable)	0.13	0.09		

Statistical analyses

No statistical analyses for this end point

Secondary: Second Extension: Incidence of Osteoporotic Clinical Lumbar Vertebral Fracture (Adjudicated)

End point title	Second Extension: Incidence of Osteoporotic Clinical Lumbar Vertebral Fracture (Adjudicated)
-----------------	--

End point description:

Osteoporotic vertebral clinical fractures were confirmed by central adjudic. using radiographic evidence on all symptomatic fractures reported as adverse experiences (excl. fractures of fingers, toes, face, & skull). Vertebral fractures were assessed for all lumbar vertebral levels (L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence of participants in the second ext. study with osteoporotic vertebral clinical fractures is provided. Due to early termination of the study, cumulative incidence using a time-to-event methodology was not assessed across base and ext. studies. The All-Participants-as-Treated Population incl. all rand. participants who entered the second ext. study and received at least one dose of open-label treatment was used for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (in the second extension)

End point values	Odanacatib 50 mg OW	Odanacatib 50 mg OW (originally assigned to placebo)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3144	2309		
Units: Percentage of Participants				
number (not applicable)	0.22	0.04		

Statistical analyses

No statistical analyses for this end point

Secondary: Second Extension: Incidence of Osteoporotic Clinical Fracture of Any Type (Adjudicated)

End point title	Second Extension: Incidence of Osteoporotic Clinical Fracture of Any Type (Adjudicated)
-----------------	---

End point description:

Osteoporotic clinical fractures of any type were confirmed by central adjudic. using radiogr. evidence on all symp. fractures reported as adverse experiences (excl. fractures of fingers, toes, face, skull). Non-vertebral fractures were assessed across mult. anat. sites incl. clavicle, dist. femur/shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, wrist; Vert. fractures assessed acr. all levels (C7/T1-12/L1-5) were incl. in analysis. Osteoporotic (fragility) fractures did not incl. fractures with traumatic/path. etiologies. Clin. fracture was defined as a fracture with related symptoms (eg, pain). The incid. proportion (cumul. incidence) of participants in 2nd ext. study with at least one osteoporotic clin. fracture of any type is provided. The All-Participants-as-Treated Popul. incl. all rand. participants who entered 2nd ext. study & received at least one dose of open-label treatment was used for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (in the second extension)

End point values	Odanacatib 50 mg OW	Odanacatib 50 mg OW (originally assigned to placebo)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3144	2309		
Units: Percentage of Participants				
number (not applicable)	2.04	2.64		

Statistical analyses

No statistical analyses for this end point

Secondary: Base Study + First Extension + Second Extension: Change in Height From Baseline Stature

End point title	Base Study + First Extension + Second Extension: Change in Height From Baseline Stature
End point description: Height was measured by wall-mounted stadiometer at randomization and at yearly intervals across the base study and the two extension studies.	
End point type	Secondary
End point timeframe: Baseline and once yearly up to 10 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[6]	0 ^[7]		
Units: cm				
arithmetic mean (confidence interval 95%)	(to)	(to)		

Notes:

[6] - The study was terminated early due to an observed increase in risk of stroke in protocol 0822-018.

[7] - The study was terminated early due to an observed increase in risk of stroke in protocol 0822-018.

Statistical analyses

No statistical analyses for this end point

Secondary: Base Study + First Extension + Second Extension: Percent Change from Baseline in BMD Measurements of the Lumbar Spine

End point title	Base Study + First Extension + Second Extension: Percent Change from Baseline in BMD Measurements of the Lumbar Spine
-----------------	---

End point description:

BMD was measured by DXA at lumbar spine starting at rand. & yearly interv. until end of study (2nd ext. study) for all participants who entered 2nd ext. study. Measurements were made on at least 3 vert. for all time points; vert. with fractures were excluded. At M96/108, approx. 3% or fewer patients in each tx group had BMD data & results at those time points should be viewed with caution. NOTE: Mean % change in BMD from baseline in participants originally rand. to placebo includes BMD results obtained

after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in base study. A longit. model with terms for tx, stratum, region & interaction b/w. tx & time as fixed effects (LS means weighted for region & stratum size) was used. The FAS popul. consisted of all rand. participants who entered 2nd ext. study & received at least one dose of open-label tx & had necessary on-tx info. (lumbar spine BMD).

End point type	Secondary
End point timeframe:	
Baseline and once yearly up to 10 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2818	2128		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 12 (n=2818, 2128)	4.68 (4.54 to 4.83)	1.01 (0.84 to 1.17)		
Month 24 (n=2803, 2121)	6.95 (6.78 to 7.12)	1.40 (1.21 to 1.59)		
Month 36 (n=2798, 2117)	8.84 (8.65 to 9.04)	1.61 (1.39 to 1.83)		
Month 48 (n=2754, 2077)	10.74 (10.51 to 10.97)	2.06 (1.80 to 2.33)		
Month 60 (n=2604, 1975)	12.55 (12.29 to 12.81)	2.45 (2.16 to 2.75)		
Month 72 (n=2068, 1594)	13.76 (13.46 to 14.06)	6.25 (5.91 to 6.59)		
Month 84 (n=1538, 1152)	14.91 (14.56 to 15.26)	8.37 (7.97 to 8.77)		
Month 96 (n=208, 177)	15.13 (14.48 to 15.78)	9.66 (8.95 to 10.38)		
Month 108 (n=56, 47)	15.54 (14.23 to 16.85)	10.85 (9.42 to 12.27)		

Statistical analyses

No statistical analyses for this end point

Secondary: Base Study + First Extension + Second Extension: Percent Change from Baseline in BMD Measurements of the Femoral Neck

End point title	Base Study + First Extension + Second Extension: Percent Change from Baseline in BMD Measurements of the Femoral Neck
-----------------	---

End point description:

BMD was measured by DXA at fem. neck starting at screening & yearly interv. until end of study (2nd ext. study) for all participants who entered 2nd ext. study. LS means % change in BMD from original baseline (BL) are provided through M108. At M96/108, approx. 3% or fewer patients in each tx group had BMD data & results at those time points should be viewed with caution. NOTE: The mean % change in BMD from BL in participants originally rand. to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in base study. A longit. model with terms for tx, stratum, region & interaction b/w tx & time as fixed effects (LS means weighted for region & stratum size) was used for analysis. The FAS popul. consisted of all rand. participants who entered 2nd ext. study & received at

least 1 dose of open-label treatment & had necessary on-treatment info. (fem. neck BMD).

End point type	Secondary
End point timeframe:	
Baseline and once yearly up to 10 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2997	2212		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 12 (n=2997, 2212)	2.89 (2.73 to 3.05)	1.06 (0.88 to 1.24)		
Month 24 (n=2965, 2189)	4.39 (4.20 to 4.57)	0.38 (0.17 to 0.60)		
Month 36 (n=2950, 2171)	6.02 (5.81 to 6.24)	-0.03 (-0.28 to 0.22)		
Month 48 (n=2905, 2133)	7.01 (6.78 to 7.25)	-0.73 (-1.01 to -0.46)		
Month 60 (n=2718, 2015)	7.98 (7.70 to 8.25)	-1.32 (-1.63 to -1.00)		
Month 72 (n=2186, 1637)	8.51 (8.21 to 8.81)	0.41 (0.06 to 0.76)		
Month 84 (n=1631, 1197)	9.11 (8.75 to 9.48)	1.56 (1.13 to 1.98)		
Month 96 (n=237, 187)	8.84 (8.22 to 9.46)	1.95 (1.24 to 2.65)		
Month 108 (n=63, 51)	9.38 (7.83 to 10.92)	3.63 (1.91 to 5.35)		

Statistical analyses

No statistical analyses for this end point

Secondary: Base Study + First Extension + Second Extension: Percent Change from Baseline in BMD Measurements of the Trochanter

End point title	Base Study + First Extension + Second Extension: Percent Change from Baseline in BMD Measurements of the Trochanter
-----------------	---

End point description:

BMD was measured by DXA at the trochanter starting at screening & at yearly intervals until end of study (2nd ext. study) for all participants who entered the 2nd ext. study. LS means % change in BMD from original BL are provided through M108. At M96/108, approx. 3% or fewer patients in each tx group had BMD data, and results at those time points should be viewed with caution. NOTE: The mean % change in BMD from BL in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in base study. A longit. model with terms for treatment, stratum, region & interaction b/w tx & time as fixed effects (LS means weighted for region & stratum size) was used. The FAS popul. consisted of all rand. participants who entered 2nd ext. study & received at least one dose of open-label tx & had the necessary on-tx info. (trochanter BMD).

End point type	Secondary
End point timeframe:	
Baseline and once yearly up to 10 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2997	2212		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 12 (n=2997, 2212)	4.55 (4.34 to 4.75)	1.81 (1.58 to 2.05)		
Month 24 (n=2965, 2189)	6.85 (6.62 to 7.08)	1.45 (1.18 to 1.72)		
Month 36 (n= 2950, 2171)	9.00 (8.73 to 9.28)	0.89 (0.57 to 1.21)		
Month 48 (n=2905, 2133)	10.58 (10.26 to 10.89)	-0.16 (-0.52 to 0.21)		
Month 60 (n= 2718, 2015)	12.21 (11.85 to 12.57)	-0.68 (-1.09 to -0.26)		
Month 72 (n=2186, 1637)	12.95 (12.55 to 13.34)	1.22 (0.76 to 1.68)		
Month 84 (n=1631, 1197)	13.30 (12.82 to 13.78)	3.17 (2.61 to 3.73)		
Month 96 (n=237, 187)	13.44 (12.67 to 14.20)	4.66 (3.79 to 5.54)		
Month 108 (n= 63, 51)	12.69 (10.86 to 14.51)	2.97 (0.95 to 5.00)		

Statistical analyses

No statistical analyses for this end point

Secondary: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated)

End point title	Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated)
-----------------	--

End point description:

Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 patient-years of follow-up) is provided. The FAS including all randomized participants who took at least one dose of study medication with follow-up from start of prime therapy to study termination (base study + first extension) was used for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part.with fracture per 100 patient-years				
number (not applicable)	0.18	0.56		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW vs Placebo.
Statistical analysis description:	
The Cox proportional hazards model included terms for treatment, stratum and geographic region.	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.24
upper limit	0.45

Secondary: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Fracture (Adjudicated)

End point title	Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Fracture (Adjudicated)
End point description:	
Osteoporotic clinical fractures (combining vertebral & non-vert.) were confirmed by central adjudic. using radiographic evidence on all symp. fractures reported as adverse experiences (excl. fractures of fingers, toes, face, skull). Vert. fractures were assessed for all levels (C7/T1-12/L1-5). Non-vert. fractures were assessed acr. multiple anat. sites incl. clav., distal femur/shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, wrist. Osteoporotic (fragility) fractures did not incl. fractures with traumatic or pathol. etiologies. A clin. fracture was defined as fracture with related symp. (eg, pain). A time-to-event methodol. was used to eval. results: the incid. rate of participants with fracture (# of participants with fracture per 100 patient-years of follow-up) is provided. The FAS incl. all rand. participants who took at least 1 dose of study medication with follow-up from start of prime therapy to study term. (base study + first ext.) was used for analysis.	
End point type	Secondary
End point timeframe:	
Up to 5 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part.with fracture per 100 patient-years				
number (not applicable)	1.95	2.93		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW vs Placebo.
Statistical analysis description: The Cox proportional hazards model included terms for treatment, stratum and geographic region.	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	0.75

Secondary: Base Study + First Extension: Percent Change from Baseline in BMD Measurements of the Total Hip

End point title	Base Study + First Extension: Percent Change from Baseline in BMD Measurements of the Total Hip
End point description: BMD was measured by DXA for all participants at the total hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp). The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (total hip BMD) was used for analysis (base study + first extension-dbp).	
End point type	Secondary
End point timeframe: Baseline, Month 6, and once yearly up to 5 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6498	6601		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 6 (n=292, 302)	1.89 (1.60 to 2.17)	0.55 (0.26 to 0.83)		
Month 12 (n=6498, 6601)	2.84 (2.75 to 2.92)	0.34 (0.26 to 0.43)		
Month 24 (n=5924, 5899)	3.79 (3.68 to 3.90)	-0.67 (-0.78 to -0.57)		
Month 36 (n=5294, 5069)	4.78 (4.65 to 4.92)	-1.67 (-1.81 to -1.54)		
Month 48 (n=3806, 3338)	5.52 (5.35 to 5.69)	-2.97 (-3.14 to -2.79)		
Month 60 (n=3180, 2599)	6.23 (6.02 to 6.44)	-4.06 (-4.28 to -3.84)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
Statistical analysis description:	
The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.94
upper limit	1.74

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description:	
The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.38
upper limit	2.62

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	4.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.31
upper limit	4.62

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	6.46

Confidence interval	
level	95 %
sides	2-sided
lower limit	6.26
upper limit	6.65

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	8.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.24
upper limit	8.73

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	10.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.99
upper limit	10.59

Secondary: Base Study + First Extension: Percent Change from Baseline in BMD Measurements of the Lumbar Spine

End point title	Base Study + First Extension: Percent Change from Baseline in
-----------------	---

End point description:

BMD was measured by DXA for all participants at the lumbar spine at randomization, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (lumbar spine BMD) was used for analysis (base study + first extension-dbp).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 5 years
--

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6220	6375		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 6 (n=291, 298)	3.72 (3.36 to 4.07)	0.82 (0.47 to 1.17)		
Month 12 (n=6220, 6375)	4.61 (4.50 to 4.71)	0.60 (0.49 to 0.70)		
Month 24 (n=5682, 5753)	6.63 (6.50 to 6.76)	0.70 (0.58 to 0.83)		
Month 36 (n=5105, 5008)	8.41 (8.26 to 8.56)	0.72 (0.56 to 0.87)		
Month 48 (n=3619, 3261)	10.19 (10.01 to 10.38)	0.85 (0.66 to 1.04)		
Month 60 (n=3066, 2547)	11.93 (11.71 to 12.15)	1.06 (0.83 to 1.29)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
----------------------------	---

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12595
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.4
upper limit	3.39

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12595
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	4.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.87
upper limit	4.15

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12595
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	5.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.75
upper limit	6.11

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	12595
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	7.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.48
upper limit	7.91

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12595
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	9.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.08
upper limit	9.61

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	12595
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	10.87

Confidence interval	
level	95 %
sides	2-sided
lower limit	10.55
upper limit	11.19

Secondary: Base Study + First Extension: Percent Change from Baseline in BMD Measurements of the Femoral Neck

End point title	Base Study + First Extension: Percent Change from Baseline in BMD Measurements of the Femoral Neck
End point description:	
BMD was measured by DXA for all participants at the femoral neck-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp). The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (femoral neck BMD) was used for analysis (base study + first extension-dbp).	
End point type	Secondary
End point timeframe:	
Baseline, Month 6, and once yearly up to 5 years	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6498	6601		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 6 (n=292, 302)	2.17 (1.78 to 2.55)	0.70 (0.32 to 1.08)		
Month 12 (n=6498, 6601)	2.81 (2.70 to 2.92)	0.60 (0.49 to 0.71)		
Month 24 (n=5924, 5899)	4.03 (3.90 to 4.16)	-0.36 (-0.49 to -0.22)		
Month 36 (n=5294, 5069)	5.48 (5.32 to 5.64)	-1.02 (-1.18 to -0.86)		
Month 48 (n=3807, 3338)	6.37 (6.17 to 6.56)	-1.93 (-2.13 to -1.73)		
Month 60 (n=3181, 2599)	7.30 (7.08 to 7.53)	-2.75 (-2.99 to -2.51)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
Statistical analysis description:	
The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	2.01

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.05
upper limit	2.37

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	4.39

Confidence interval	
level	95 %
sides	2-sided
lower limit	4.2
upper limit	4.57

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.28
upper limit	6.72

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	8.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.02
upper limit	8.57

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	10.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.72
upper limit	10.38

Secondary: Base Study + First Extension: Percent Change from Baseline in BMD Measurements of the Trochanter

End point title	Base Study + First Extension: Percent Change from Baseline in BMD Measurements of the Trochanter
-----------------	--

End point description:

BMD was measured by DXA for all participants at the trochanter-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp). The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (trochanter BMD) was used for analysis (base study + first extension-dbp).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, and once yearly up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6498	6601		
Units: g/cm ²				
least squares mean (confidence interval 95%)				
Month 6 (n=292, 302)	2.70 (2.21 to 3.18)	0.95 (0.47 to 1.43)		
Month 12 (n=6498, 6601)	4.33 (4.19 to 4.47)	0.83 (0.69 to 0.97)		
Month 24 (n=5924, 5899)	6.17 (6.00 to 6.34)	-0.23 (-0.40 to -0.06)		
Month 36 (n=5294, 5069)	7.96 (7.75 to 8.16)	-1.29 (-1.50 to -1.08)		
Month 48 (n=3806, 3338)	9.27 (9.01 to 9.53)	-2.86 (-3.13 to -2.59)		
Month 60 (n=3180, 2599)	10.66 (10.36 to 10.97)	-3.90 (-4.22 to -3.57)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 6.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.06
upper limit	2.42

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.31
upper limit	3.7

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24
-----------------------------------	---

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment &

time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	6.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.16
upper limit	6.65

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	9.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.95
upper limit	9.54

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	12.14

Confidence interval	
level	95 %
sides	2-sided
lower limit	11.76
upper limit	12.51

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60.
-----------------------------------	--

Statistical analysis description:

The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	13099
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	14.56

Confidence interval	
level	95 %
sides	2-sided
lower limit	14.11
upper limit	15.01

Secondary: Base Study + First Extension: Percent Change from Baseline in BMD Measurements of the Distal-Third Forearm

End point title	Base Study + First Extension: Percent Change from Baseline in BMD Measurements of the Distal-Third Forearm
-----------------	--

End point description:

BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study + first extension-dbp) in an approximate 10% random subset of participants at selected sites. The FAS population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (distal one-third radius BMD) was used for analysis (base study + first extension-dbp).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and once yearly up to 5 years

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	679	718		
Units: g/cm ²				
least squares mean (confidence interval 95%)				

Month 12 (n=679, 718)	0.50 (0.18 to 0.81)	-0.61 (-0.91 to -0.30)		
Month 24 (n=619, 634)	0.33 (-0.01 to 0.68)	-1.02 (-1.37 to -0.68)		
Month 36 (n=576, 564)	0.05 (-0.33 to 0.43)	-1.91 (-2.29 to -1.53)		
Month 48 (n=251, 217)	-0.30 (-0.84 to 0.23)	-2.49 (-3.05 to -1.92)		
Month 60 (n=328, 263)	-0.84 (-1.37 to -0.31)	-3.17 (-3.74 to -2.59)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 12.
Statistical analysis description:	
The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	1.54

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 24.
Statistical analysis description:	
The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.87
upper limit	1.85

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 36.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.42
upper limit	2.5

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 48.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.4
upper limit	2.96

Statistical analysis title	Odanacatib 50 mg OW - Placebo at Month 60.
Statistical analysis description: The longitudinal model includes terms for treatment, stratum, region & interaction between treatment & time as fixed effects (LS means weighted for region & stratum size).	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	1397
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.54
upper limit	3.11

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography
-----------------	--

End point description:

Compartment-specific effects of osteoporosis were assessed by measuring cortical vBMD at the total hip using quantitative computed tomography. The percent change from baseline at Month 24 was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture [yes/no]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (total hip cortical vBMD) was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	55		
Units: mg/cm ³				
least squares mean (confidence interval 95%)	3.29 (2.33 to 4.24)	0.52 (-0.39 to 1.44)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.43
upper limit	4.1

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in Areal BMD (aBMD) of the Lumbar Spine Using DXA

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in Areal BMD (aBMD) of the Lumbar Spine Using DXA
End point description:	aBMD was measured at the lumbar spine (L1 to L4) at baseline and Month 24 using DXA . If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from analysis. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (lumbar spine aBMD) was used for analysis (PN032-Base).
End point type	Secondary
End point timeframe:	Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	59		
Units: g/cm ²				
least squares mean (confidence interval 95%)	5.63 (4.54 to 6.72)	0.08 (-0.92 to 1.09)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	109
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	5.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.06
upper limit	7.05

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Total Hip Using DXA

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Total Hip Using DXA
-----------------	--

End point description:

aBMD was measured at the total hip at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (total hip aBMD) was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	49	58		
Units: g/cm ²				
least squares mean (confidence interval 95%)	2.96 (2.03 to 3.90)	-0.66 (-1.52 to 0.20)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	3.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.35
upper limit	4.9

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA
-----------------	---

End point description:

aBMD was measured at the femoral neck at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (femoral neck aBMD) was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	49	58		
Units: g/cm ²				
least squares mean (confidence interval 95%)	3.15 (1.74 to 4.56)	0.36 (-0.94 to 1.65)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.005
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	2.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	4.72

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Trochanter Using DXA

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Trochanter Using DXA
-----------------	---

End point description:

aBMD was measured at the trochanter at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (trochanter aBMD) was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	49	58		
Units: g/cm ²				
least squares mean (confidence interval 95%)	5.10 (3.74 to 6.45)	-0.55 (-1.80 to 0.70)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	5.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.79
upper limit	7.5

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Distal-Third Forearm Using DXA

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Distal-Third Forearm Using DXA
-----------------	---

End point description:

aBMD was measured at the the distal one-third radius at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (trochanter aBMD) was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	49	55		
Units: g/cm ²				
least squares mean (confidence interval 95%)	0.40 (-0.57 to 1.36)	-1.27 (-2.18 to -0.36)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.016
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	1.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	3.01

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in s-CTx After Log-Transformation

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in s-CTx After Log-Transformation
-----------------	---

End point description:

s-CTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction from baseline in s-CTx was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided. The per-protocol population including all randomized patients who took at least one dose of study medication and having the necessary on-treatment information (s-CTx) and excluding participants and/or data points that represent clinically important deviations from the protocol-specified criteria was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	36	45		
Units: ng/mL				
geometric mean (confidence interval 95%)	-55.62 (-62.53 to -47.44)	6.62 (-8.51 to 24.26)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS Means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-62.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-79.99
upper limit	-44.5

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in u-NTx/Cr Ratio After Log-Transformation

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in u-NTx/Cr Ratio After Log-Transformation
-----------------	--

End point description:

u-NTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at baseline & M24 in an approx. 10% random subset participants at selected sites in P018 base study who were additionally included in imaging substudy PN032-base study. Urine NTx measurements (in BCE) were normalized to urine Cr concentration (i.e., u-NTx/Cr ratio) & the log-transformed fraction from baseline in u-NTx/Cr ratio was then determined using a longit. model with terms for tx, stratum, & interaction b/w tx & time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for % change from baseline are provided. The per-protocol population incl. all rand. participants who took at least one dose of study medication & having necessary on-tx information (u-NTx/Cr) & excl. participants and/or data points that represent clinically important deviations from protocol-specified criteria was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	36	45		
Units: nmol BCE/mmol				
geometric mean (confidence interval 95%)	-47.87 (-57.26 to -36.42)	16.56 (-2.85 to 39.84)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS Means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-64.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	-87.8
upper limit	-41.07

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in BSAP After Log-Transformation

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in BSAP After Log-Transformation
-----------------	--

End point description:

BSAP is an enzyme produced by matrix-synthesizing osteoblasts during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum BSAP was assessed at baseline & M24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction from baseline in BSAP was determined using a longitudinal model with terms for tx, stratum, & interaction between tx & time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided. The per-protocol population incl. all rand. patients who took at least one dose of study medication & having the necessary on-tx information (BSAP) & excl. participants and/or data points that represent clinically important deviations from the protocol-specified criteria was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	36	45		
Units: ng/mL				
geometric mean (confidence interval 95%)	-12.39 (-19.20 to -4.99)	12.64 (4.53 to 21.38)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS Means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-25.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.92
upper limit	-14.12

Secondary: Imaging Substudy PN032-Base: Percent Change From Baseline in P1NP After Log-Transformation

End point title	Imaging Substudy PN032-Base: Percent Change From Baseline in P1NP After Log-Transformation
-----------------	--

End point description:

P1NP is a cleavage fragment produced during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum P1NP was assessed at baseline and Month 24 in an approx. 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction change from baseline in P1NP was determined using a longitudinal model with terms for treatment, stratum, & interaction b/w treatment & time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for % change from baseline are provided. The per-protocol population including all rand. patients who took at least one dose of study medication & having the necessary on-treatment information (P1NP) & excl. participants and/or data points that represent clinically important deviations from the protocol-specified criteria was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 24

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	36	45		
Units: ng/mL				
geometric mean (confidence interval 95%)	-33.56 (-42.66 to -23.01)	-6.86 (-18.71 to 6.72)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum and interaction between treatment and time as fixed effects (LS Means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	-26.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-42.56
upper limit	-10.83

Secondary: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography

End point title	Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography
-----------------	--

End point description:

Compartment-specific effects of osteoporosis were assessed by measuring cortical vBMD at the total hip using quantitative computed tomography. The percent change from baseline at Month 60 (base study + extension study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture [yes/no]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (total hip cortical vBMD) was used for analysis (PN032-Base).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 60

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	27		
Units: mg/cm ³				
least squares mean (confidence interval 95%)	6.00 (4.07 to 7.93)	-2.53 (-4.48 to -0.59)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum (prior vertebral fracture (yes/no)) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	8.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.79
upper limit	11.28

Secondary: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Lumbar Spine Using DXA

End point title	Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Lumbar Spine Using DXA
End point description:	aBMD was measured at the lumbar spine (L1 to L4) at baseline and Month 60 using DXA . If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from analysis. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (lumbar spine aBMD) was used for analysis (PN032-Base + Extension).
End point type	Secondary
End point timeframe:	
Baseline, Month 60	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	36	37		
Units: g/cm ²				
least squares mean (confidence interval 95%)	11.80 (9.86 to 13.73)	0.72 (-1.10 to 2.54)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	Longitudinal model with terms for treatment, stratum (prior vertebral fracture (yes/no)) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	11.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.41
upper limit	13.74

Secondary: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Total Hip Using DXA

End point title	Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Total Hip Using DXA
-----------------	--

End point description:

aBMD was measured at the total hip at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (total hip aBMD) was used for analysis (PN032-Base + Extension).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 60

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	35		
Units: g/cm ²				
least squares mean (confidence interval 95%)	5.34 (3.66 to 7.01)	-5.07 (-6.74 to -3.41)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum (prior vertebral fracture (yes/no)) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	10.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.05
upper limit	12.78

Secondary: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA

End point title	Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA
-----------------	---

End point description:

aBMD was measured at the femoral neck at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (femoral neck aBMD) was used for analysis (PN032-Base + Extension).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 60

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	35		
Units: g/cm ²				
least squares mean (confidence interval 95%)	6.87 (4.68 to 9.06)	-3.11 (-5.26 to -0.96)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum (prior vertebral fracture (yes/no)) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	9.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.91
upper limit	13.06

Secondary: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Trochanter Using DXA

End point title	Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Trochanter Using DXA
-----------------	---

End point description:

aBMD was measured at the trochanter at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size). The FAS including consisting of all randomized participants who took at least one dose of blinded study treatment and have a baseline and at least one on-treatment measurement available (trochanter aBMD) was used for analysis (PN032-Base + Extension).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 60

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	35		
Units: g/cm ²				
least squares mean (confidence interval 95%)	10.44 (7.84 to 13.03)	-4.50 (-7.07 to -1.94)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Longitudinal model with terms for treatment, stratum (prior vertebral fracture (yes/no)) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Longitudinal model
Parameter estimate	Mean difference (final values)
Point estimate	14.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.29
upper limit	18.59

Secondary: Base Study: Time to First 4-Point MACE Confirmed by TIMI Adjudication

End point title	Base Study: Time to First 4-Point MACE Confirmed by TIMI Adjudication
-----------------	---

End point description:

The time to first TIMI-adjudicated 4-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, 3. non-fatal definite stroke, or 4. hospitalization for unstable angina) was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	1.25	1.12		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region.

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.181
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.95
upper limit	1.32

Secondary: Base Study: Time to First All-Cause Death Confirmed by TIMI Adjudication

End point title	Base Study: Time to First All-Cause Death Confirmed by TIMI Adjudication
-----------------	--

End point description:

The time to first TIMI-adjudicated all-cause death was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	1.56	1.38		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region.

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.102
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	1.3

Secondary: Base Study: Time to First Cardiovascular Death Confirmed by TIMI Adjudication

End point title	Base Study: Time to First Cardiovascular Death Confirmed by TIMI Adjudication
-----------------	---

End point description:

The time to first TIMI-adjudicated cardiovascular death was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.45	0.38		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.277
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.89
upper limit	1.52

Secondary: Base Study: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication

End point title	Base Study: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication
End point description:	The time to first TIMI-adjudicated fatal or non-fatal definite myocardial infarction was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).
End point type	Secondary
End point timeframe:	Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.25	0.31		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	Cox proportional hazards model with terms for treatment, stratum and geographic region
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.256
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	1.15

Secondary: Base Study: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication

End point title	Base Study: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication
-----------------	--

End point description:

The time to first TIMI-adjudicated fatal definite myocardial infarction was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.03	0.03		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.794
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.29
upper limit	2.57

Secondary: Base Study: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication

End point title	Base Study: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication
-----------------	--

End point description:

The time to first TIMI-adjudicated fatal or non-fatal definite stroke was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.58	0.44		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.034
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.02
upper limit	1.7

Secondary: Base Study: Time to First Fatal Stroke Confirmed by TIMI Adjudication

End point title	Base Study: Time to First Fatal Stroke Confirmed by TIMI Adjudication
-----------------	---

End point description:

The time to first TIMI-adjudicated fatal definite stroke was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.09	0.05		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.081
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	3.97

Secondary: Base Study: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication

End point title	Base Study: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication
End point description:	
The time to first TIMI-adjudicated hospitalization for unstable angina was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).	
End point type	Secondary
End point timeframe:	
Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.10	0.09		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	
Cox proportional hazards model with terms for treatment, stratum and geographic region	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.857
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	1.89

Secondary: Base Study: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication

End point title	Base Study: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
-----------------	--

End point description:

The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was required. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.25	0.23		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.606
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.59

Secondary: Base Study: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication

End point title	Base Study: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
-----------------	--

End point description:

The time to first TIMI-adjudicated any reported episode of atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were included and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacetib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.60	0.48		

Statistical analyses

Statistical analysis title	Odanacetib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacetib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.074
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	1.6

Secondary: Base Study + First Extension: Time to First 4-Point MACE Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First 4-Point MACE Confirmed by TIMI Adjudication
-----------------	---

End point description:

The time to first TIMI-adjudicated 4-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, 3. non-fatal definite stroke, or 4. hospitalization for unstable angina) was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	1.31	1.15		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.062
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.31

Secondary: Base Study + First Extension: Time to First All-Cause Death Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First All-Cause Death Confirmed by TIMI Adjudication
-----------------	--

End point description:

The time to first TIMI-adjudicated all-cause death was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	1.79	1.70		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.341
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.95
upper limit	1.17

Secondary: Base Study + First Extension: Time to First Cardiovascular Death Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First Cardiovascular Death Confirmed by TIMI Adjudication
End point description:	The time to first TIMI-adjudicated cardiovascular death was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).
End point type	Secondary
End point timeframe:	Up to 5 years (Data cutoff April 2016)

End point values	Odanacetib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.48	0.43		

Statistical analyses

Statistical analysis title	Odanacetib 50 mg OW - Placebo
Statistical analysis description:	Cox proportional hazards model with terms for treatment, stratum and geographic region
Comparison groups	Odanacetib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.246
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	1.4

Secondary: Base Study + First Extension: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication
-----------------	---

End point description:

The time to first TIMI-adjudicated fatal or non-fatal definite myocardial infarction was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.26	0.28		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.675
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.26

Secondary: Base Study + First Extension: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication
End point description:	The time to first TIMI-adjudicated fatal definite myocardial infarction was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).
End point type	Secondary
End point timeframe:	Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.02	0.03		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	Cox proportional hazards model with terms for treatment, stratum and geographic region
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.638
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	2.03

Secondary: Base Study + First Extension: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication
End point description:	The time to first TIMI-adjudicated fatal or non-fatal definite stroke was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).
End point type	Secondary
End point timeframe:	Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.58	0.42		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	Cox proportional hazards model with terms for treatment, stratum and geographic region
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.005
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.1
upper limit	1.71

Secondary: Base Study + First Extension: Time to First Fatal Stroke Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First Fatal Stroke Confirmed by TIMI Adjudication
-----------------	---

End point description:

The time to first TIMI-adjudicated fatal definite stroke was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacetib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.09	0.05		

Statistical analyses

Statistical analysis title	Odanacetib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacetib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.114
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.89
upper limit	2.9

Secondary: Base Study + First Extension: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication
End point description:	The time to first TIMI-adjudicated hospitalization for unstable angina was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).
End point type	Secondary
End point timeframe:	Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.08	0.10		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description:	Cox proportional hazards model with terms for treatment, stratum and geographic region
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.366
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.33

Secondary: Base Study + First Extension: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
-----------------	--

End point description:

The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was required. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study + first extension).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.27	0.22		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
----------------------------	-------------------------------

Statistical analysis description:

Cox proportional hazards model with terms for treatment, stratum and geographic region

Comparison groups	Odanacatib 50 mg OW v Placebo
-------------------	-------------------------------

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.198
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	1.68

Secondary: Base Study + First Extension: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication

End point title	Base Study + First Extension: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
End point description: The time to first TIMI-adjudicated any reported episode of atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were included and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 patient-years of follow-up. Results from MK-0822-083, a follow up study to the MK-0822-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are included. The All-Participants-as-Treated population including all randomized participants who took at least one dose of study medication was used for analysis (base study).	
End point type	Secondary
End point timeframe: Up to 5 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (not applicable)	0.61	0.50		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Statistical analysis description: Cox proportional hazards model with terms for treatment, stratum and geographic region	
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.059
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.5

Post-hoc: Base Study: Incidence Rate of Femoral Shaft Fractures Confirmed by Adjudication

End point title	Base Study: Incidence Rate of Femoral Shaft Fractures Confirmed by Adjudication
-----------------	---

End point description:

The incidence rate of femoral shaft fracture events (including both atypical and non-atypical; of any etiology including traumatic) confirmed by adjudication was determined for the base study. Results are expressed as number of participants with an event per 100 patient-years of follow-up. The All-Participants-as-Treated population including all randomized patients who took at least one dose of study medication was used for analysis (base study).

End point type	Post-hoc
----------------	----------

End point timeframe:

Up to 4 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (confidence interval 95%)	0.10 (0.06 to 0.15)	0.06 (0.03 to 0.10)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
Method	Miettinen & Nurminen
Parameter estimate	Difference in rates
Point estimate	0.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.01
upper limit	0.09

Post-hoc: Base Study: Incidence Rate of Atypical Femoral Shaft Fractures Confirmed by Adjudication

End point title	Base Study: Incidence Rate of Atypical Femoral Shaft Fractures Confirmed by Adjudication
End point description:	
Atypical subtrochanteric/diaphyseal femoral fractures (AFF) are an uncommon type of low-energy (eg, osteoporotic) femoral shaft fracture of unclear causation infrequently reported in osteoporotic persons treated with long-term anti-resorptive therapy (eg, bisphosphonates). All femoral (femur, femur-distal, femur-shaft) fractures in the base study were adjudicated against both ASBMR 2010 and 2013 criteria . All 5 major features (ie, location along femoral shaft, no/minimal trauma, transverse/short oblique fracture, non-comminuted, complete/incomplete fracture) were required for ASBMR 2010 AFF case definition; while 4 of 5 major features (ie, no/minimal trauma, substantially transverse orientation at cortical origin with possible oblique orientation medially, non-comminuted/minimally comminuted, complete/incomplete fracture, localized periosteal reaction of lateral cortex) with requirement for location along femoral shaft were required for ASBMR 2013 AFF case definition.	
End point type	Post-hoc
End point timeframe:	
Up to 4 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (confidence interval 95%)	0.02 (0.01 to 0.05)	0.00 (0.00 to 0.02)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Comparison groups	Odanacatib 50 mg OW v Placebo

Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
Method	Miettinen & Nurminen
Parameter estimate	Difference in rates
Point estimate	0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.01
upper limit	0.05

Post-hoc: Base Study + First Extension: Incidence Rate of Femoral Shaft Fractures Confirmed by Adjudication

End point title	Base Study + First Extension: Incidence Rate of Femoral Shaft Fractures Confirmed by Adjudication
End point description: The incidence rate of femoral shaft fracture events (including both atypical and non-atypical; of any etiology including traumatic) confirmed by adjudication was determined for the base study + first extension. Results are expressed as number of participants with an event per 100 patient-years of follow-up.	
End point type	Post-hoc
End point timeframe: Up to 4 years (Data cutoff April 2016)	

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (confidence interval 95%)	0.09 (0.06 to 0.13)	0.02 (0.01 to 0.05)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
Method	Miettinen & Nurminen
Parameter estimate	Difference in rates
Point estimate	0.06

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.03
upper limit	0.11

Post-hoc: Base Study + First Extension: Incidence Rate of Atypical Femoral Shaft Fractures Confirmed by Adjudication

End point title	Base Study + First Extension: Incidence Rate of Atypical Femoral Shaft Fractures Confirmed by Adjudication
-----------------	--

End point description:

Atypical subtrochanteric/diaphyseal femoral fractures (AFF) are an uncommon type of low-energy (eg, osteoporotic) femoral shaft fracture of unclear causation infrequently reported in osteoporotic persons treated with long-term anti-resorptive therapy (eg, bisphosphonates). All femoral (femur, femur-distal, femur-shaft) fractures in the base study + first extension were adjudicated against both ASBMR 2010 & 2013 criteria. All 5 major features (ie, location along femoral shaft, no/minimal trauma, transverse/short oblique fracture, non-comminuted, complete/incomplete fracture) were required for ASBMR 2010 AFF case definition; while 4 of 5 major features (ie, no/minimal trauma, substantially transverse orientation at cortical origin with possible oblique orientation medially, non-comminuted/minimally comminuted, complete/incomplete fracture, localized periosteal reaction of lateral cortex) with requirement for location along femoral shaft were required for ASBMR 2013 AFF case definition.

End point type	Post-hoc
----------------	----------

End point timeframe:

Up to 4 years (Data cutoff April 2016)

End point values	Odanacatib 50 mg OW	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8043	8028		
Units: Part. with event per 100 patient-years				
number (confidence interval 95%)	0.03 (0.02 to 0.06)	0.00 (0.00 to 0.01)		

Statistical analyses

Statistical analysis title	Odanacatib 50 mg OW - Placebo
Comparison groups	Odanacatib 50 mg OW v Placebo
Number of subjects included in analysis	16071
Analysis specification	Pre-specified
Analysis type	other
Method	Miettinen & Nurminen
Parameter estimate	Difference in rates
Point estimate	0.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.02
upper limit	0.06

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 10 years

Adverse event reporting additional description:

The All-Participants-as-Treated population including all randomized patients who took at least one dose of study medication was used for analysis (base study + first extension; second extension).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.1
--------------------	------

Reporting groups

Reporting group title	Base Study + First Extension: Odanacatib 50 mg OW
-----------------------	---

Reporting group description:

Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total). Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Reporting group title	Base Study + First Extension: Placebo
-----------------------	---------------------------------------

Reporting group description:

Participants receive blinded placebo to 10 mg of odanacatib weekly over the course of the base study and first extension study (5 years total). Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Reporting group title	Second Extension: Odanacatib 50 mg OW
-----------------------	---------------------------------------

Reporting group description:

Participants receive 50 mg of open-label odanacatib weekly for 5 years in the second extension study after having previously received 50 mg of blinded odanacatib weekly in the base study and first extension study (5 years total). Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Reporting group title	Second Extension: Odanacatib 50 mg OW (Placebo)
-----------------------	---

Reporting group description:

Participants receive 50 mg of open-label odanacatib weekly for 5 years in the second extension study after having previously received blinded placebo to 50 mg of odanacatib weekly in the base study and first extension study (5 years total). Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.

Serious adverse events	Base Study + First Extension: Odanacatib 50 mg OW	Base Study + First Extension: Placebo	Second Extension: Odanacatib 50 mg OW
Total subjects affected by serious adverse events			
subjects affected / exposed	2441 / 8043 (30.35%)	2446 / 8028 (30.47%)	508 / 3144 (16.16%)
number of deaths (all causes)	378	327	86
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Abdominal neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute leukaemia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Adenocarcinoma gastric			
subjects affected / exposed	4 / 8043 (0.05%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 0
Adenocarcinoma of appendix			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	10 / 8043 (0.12%)	7 / 8028 (0.09%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 10	0 / 8	0 / 2
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Adenocarcinoma of the cervix			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal cancer			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angiosarcoma			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Astrocytoma			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
B-cell lymphoma			
subjects affected / exposed	4 / 8043 (0.05%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	79 / 8043 (0.98%)	71 / 8028 (0.88%)	9 / 3144 (0.29%)
occurrences causally related to treatment / all	0 / 93	0 / 87	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign gastric neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign breast neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign lung neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign muscle neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign neoplasm of bladder			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign neoplasm of thyroid gland			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign neoplasm of skin			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign salivary gland neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign vulval neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct cancer			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder transitional cell carcinoma			

subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone cancer			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Borderline mucinous tumour of ovary			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bowen's disease			
subjects affected / exposed	6 / 8043 (0.07%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain cancer metastatic			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	33 / 8043 (0.41%)	32 / 8028 (0.40%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 33	0 / 32	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Brain neoplasm			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer in situ			

subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer recurrent			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer metastatic			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Breast cancer stage III			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial carcinoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchioloalveolar carcinoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carcinoid tumour of the stomach			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carcinoma in situ of skin			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac myxoma			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar tumour			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellopontine angle tumour			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervix cancer metastatic			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cervix carcinoma			
subjects affected / exposed	6 / 8043 (0.07%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 6	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervix carcinoma recurrent			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervix carcinoma stage II			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Chondroma			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choroid melanoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic lymphocytic leukaemia			
subjects affected / exposed	3 / 8043 (0.04%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon adenoma			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clear cell endometrial carcinoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	23 / 8043 (0.29%)	17 / 8028 (0.21%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 23	0 / 17	0 / 4
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 0
Colon cancer metastatic			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Colon neoplasm			

subjects affected / exposed	0 / 8043 (0.00%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Colorectal cancer recurrent			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diffuse large B-cell lymphoma stage IV			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ductal adenocarcinoma of pancreas			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysplastic naevus			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial adenocarcinoma			
subjects affected / exposed	4 / 8043 (0.05%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial cancer			
subjects affected / exposed	4 / 8043 (0.05%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Essential thrombocythaemia			

subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fallopian tube cancer			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Female reproductive neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Fibroadenoma of breast			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibromatosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibroma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Follicle centre lymphoma, follicular grade I, II, III stage II			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder adenocarcinoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Gallbladder cancer			

subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 2	1 / 1	0 / 0
Gastric cancer			
subjects affected / exposed	5 / 8043 (0.06%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 0
Gastric cancer stage IV			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Gastric neoplasm			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Gastrointestinal carcinoma			
subjects affected / exposed	0 / 8043 (0.00%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Gastrointestinal neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stromal tumour			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal tract adenoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingival cancer			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioblastoma			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Glioblastoma multiforme			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomus tumour			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemangioma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemangioma of bone			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cancer			
subjects affected / exposed	5 / 8043 (0.06%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 4	0 / 2	0 / 1
Hepatic neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hepatocellular carcinoma			

subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Inflammatory carcinoma of the breast			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Intraductal papilloma of breast			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraductal proliferative breast lesion			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraocular melanoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	7 / 8043 (0.09%)	5 / 8028 (0.06%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 7	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive lobular breast carcinoma			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kaposi's sarcoma			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratoacanthoma			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal squamous cell carcinoma			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lentigo maligna			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukaemia			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lip and/or oral cavity cancer			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Lip squamous cell carcinoma			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liposarcoma			
subjects affected / exposed	0 / 8043 (0.00%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lobular breast carcinoma in situ			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			
subjects affected / exposed	8 / 8043 (0.10%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 4	0 / 0	0 / 0
Lung adenocarcinoma stage I			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma stage IV			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lung cancer metastatic			
subjects affected / exposed	2 / 8043 (0.02%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Lung carcinoma cell type unspecified stage IV			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Lung neoplasm			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	13 / 8043 (0.16%)	23 / 8028 (0.29%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 13	0 / 24	0 / 4
deaths causally related to treatment / all	0 / 6	0 / 5	0 / 2
Lymphangioma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoma			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lymphoproliferative disorder			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	6 / 8043 (0.07%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma in situ			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm of ampulla of Vater			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm of eyelid			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm of renal pelvis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Malignant neoplasm of unknown primary site			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Malignant peritoneal neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mantle cell lymphoma			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medullary thyroid cancer			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melanocytic naevus			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melanoma recurrent			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesothelioma			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Meningioma			
subjects affected / exposed	3 / 8043 (0.04%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesothelioma malignant			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metaplastic breast carcinoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to central nervous system			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to liver			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Metastases to lung			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Metastases to lymph nodes			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metastases to peritoneum			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to pleura			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to skin			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastasis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metastatic bronchial carcinoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metastatic gastric cancer			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metastatic malignant melanoma			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic neoplasm			
subjects affected / exposed	4 / 8043 (0.05%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 3	0 / 1	0 / 0
Metastatic salivary gland cancer			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic uterine cancer			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mixed adenoneuroendocrine carcinoma			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucinous breast carcinoma			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mycosis fungoides			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome transformation			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myeloproliferative disorder			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal cavity cancer			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nasal neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngeal cancer			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm malignant			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Neuroendocrine carcinoma			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Neuroendocrine carcinoma metastatic			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Neuroendocrine tumour			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-Hodgkin's lymphoma			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Non-small cell lung cancer			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer metastatic			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Non-small cell lung cancer stage IV			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Oesophageal adenocarcinoma			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Oesophageal carcinoma			
subjects affected / exposed	3 / 8043 (0.04%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	2 / 3	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 1
Oesophageal squamous cell carcinoma			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oligodendroglioma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal cancer			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Osteoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteosarcoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ovarian adenoma			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer			
subjects affected / exposed	7 / 8043 (0.09%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	1 / 7	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 0
Ovarian cancer metastatic			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ovarian epithelial cancer stage I			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			
subjects affected / exposed	13 / 8043 (0.16%)	9 / 8028 (0.11%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 13	0 / 9	0 / 3
deaths causally related to treatment / all	0 / 7	0 / 6	0 / 2
Pancreatic carcinoma metastatic			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 1
Pancreatic carcinoma stage IV			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic neoplasm			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Papillary serous endometrial carcinoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	1 / 8043 (0.01%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papilloma			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parathyroid tumour benign			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal mesothelioma malignant			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal cancer			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	6 / 8043 (0.07%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasmacytoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Primary myelofibrosis			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyogenic granuloma			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal adenocarcinoma			
subjects affected / exposed	3 / 8043 (0.04%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Rectal adenoma			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal cancer			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectosigmoid cancer			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Refractory anaemia with an excess of blasts			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Refractory cytopenia with unilineage dysplasia			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cancer			
subjects affected / exposed	3 / 8043 (0.04%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Renal cell carcinoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma stage II			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal oncocytoma			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal cancer			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salivary gland cancer			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sarcoma			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Schwannoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seborrhoeic keratosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin cancer			
subjects affected / exposed	3 / 8043 (0.04%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small cell lung cancer			
subjects affected / exposed	5 / 8043 (0.06%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 4	0 / 0	0 / 0
Small cell lung cancer limited stage			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord neoplasm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Splenic marginal zone lymphoma			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	14 / 8043 (0.17%)	12 / 8028 (0.15%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 14	0 / 12	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Squamous cell carcinoma of lung			
subjects affected / exposed	1 / 8043 (0.01%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	18 / 8043 (0.22%)	10 / 8028 (0.12%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 20	0 / 10	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the cervix			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Squamous cell carcinoma of the tongue			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Superficial spreading melanoma stage unspecified			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

T-cell lymphoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Thymoma malignant			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid adenoma			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cancer			
subjects affected / exposed	1 / 8043 (0.01%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cancer metastatic			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tongue neoplasm malignant stage unspecified			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsil cancer			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell cancer of the renal pelvis and ureter			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ureteric cancer			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine cancer			
subjects affected / exposed	3 / 8043 (0.04%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	7 / 8043 (0.09%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 7	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine neoplasm			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulval cancer			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulval cancer stage 0			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to bone			

subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Urethral cancer			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the vagina			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic aneurysm			
subjects affected / exposed	8 / 8043 (0.10%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 9	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Aortic aneurysm rupture			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Aortic arteriosclerosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic disorder			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			

subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Arterial disorder			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic stenosis			
subjects affected / exposed	3 / 8043 (0.04%)	4 / 8028 (0.05%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial stenosis			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriosclerosis			
subjects affected / exposed	5 / 8043 (0.06%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Bleeding varicose vein			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood pressure fluctuation			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Circulatory collapse			
subjects affected / exposed	2 / 8043 (0.02%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Deep vein thrombosis			

subjects affected / exposed	17 / 8043 (0.21%)	9 / 8028 (0.11%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 19	0 / 9	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Distributive shock			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Essential hypertension			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iliac artery embolism			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extremity necrosis			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Femoral artery occlusion			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	5 / 8043 (0.06%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hot flush			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			

subjects affected / exposed	31 / 8043 (0.39%)	37 / 8028 (0.46%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	1 / 34	0 / 39	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hypertensive crisis			
subjects affected / exposed	10 / 8043 (0.12%)	20 / 8028 (0.25%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 12	0 / 21	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Hypertensive emergency			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hypotension			
subjects affected / exposed	7 / 8043 (0.09%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 7	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hypovolaemic shock			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Iliac artery occlusion			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infarction			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intermittent claudication			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant hypertension			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrosis ischaemic			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	5 / 8043 (0.06%)	4 / 8028 (0.05%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			
subjects affected / exposed	7 / 8043 (0.09%)	5 / 8028 (0.06%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 8	0 / 6	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery stenosis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery thrombosis			
subjects affected / exposed	4 / 8043 (0.05%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral circulatory failure			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral vascular disorder			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral venous disease			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock haemorrhagic			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Subgaleal haematoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Temporal arteritis			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis			
subjects affected / exposed	0 / 8043 (0.00%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis superficial			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			

subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicose ulceration			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicose vein			
subjects affected / exposed	8 / 8043 (0.10%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 8	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vena cava thrombosis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Accidental death			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 0
Adverse event			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	7 / 8043 (0.09%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 0
Capsular contracture associated with breast implant			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	22 / 8043 (0.27%)	24 / 8028 (0.30%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 23	0 / 25	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cyst			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	66 / 8043 (0.82%)	62 / 8028 (0.77%)	14 / 3144 (0.45%)
occurrences causally related to treatment / all	0 / 66	0 / 62	0 / 14
deaths causally related to treatment / all	0 / 66	0 / 62	0 / 14
Device adhesion issue			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device breakage			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device damage			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device dislocation			
subjects affected / exposed	4 / 8043 (0.05%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device malfunction			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device material issue			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug intolerance			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug withdrawal syndrome			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial pain			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			

subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General symptom			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hernia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ill-defined disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Impaired healing			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site reaction			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device complication			

subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multi-organ disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Multi-organ failure			
subjects affected / exposed	10 / 8043 (0.12%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 10	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 9	0 / 6	0 / 0
Nodule			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	5 / 8043 (0.06%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	4 / 8043 (0.05%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral administration complication			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral swelling			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	4 / 8043 (0.05%)	7 / 8028 (0.09%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue inflammation			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Strangulated hernia			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	15 / 8043 (0.19%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 15	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 15	0 / 2	0 / 0
Systemic inflammatory response syndrome			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Immune system disorders			
Anaphylactic reaction			

subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic shock			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sarcoidosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Immobile			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Adnexal torsion			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adnexa uteri mass			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Anisomastia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast mass			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical dysplasia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical polyp			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colpocele			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystocele			
subjects affected / exposed	7 / 8043 (0.09%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 7	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysfunctional uterine bleeding			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial hyperplasia			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital labial adhesions			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrometra			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metrorrhagia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst			
subjects affected / exposed	12 / 8043 (0.15%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 12	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic floor muscle weakness			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic prolapse			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postmenopausal haemorrhage			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectocele			

subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine polyp			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal polyp			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine prolapse			
subjects affected / exposed	14 / 8043 (0.17%)	13 / 8028 (0.16%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 15	0 / 14	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal fistula			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal prolapse			
subjects affected / exposed	7 / 8043 (0.09%)	10 / 8028 (0.12%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 7	0 / 10	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulval leukoplakia			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulvar dysplasia			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical leukoplakia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital prolapse			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	3 / 8043 (0.04%)	9 / 8028 (0.11%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 9	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 4	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	4 / 8043 (0.05%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 3	0 / 3	0 / 0
Aspiration			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Asthma			

subjects affected / exposed	10 / 8043 (0.12%)	17 / 8028 (0.21%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 11	0 / 20	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Asthmatic crisis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiectasis			
subjects affected / exposed	2 / 8043 (0.02%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Atelectasis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis chronic			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	34 / 8043 (0.42%)	36 / 8028 (0.45%)	9 / 3144 (0.29%)
occurrences causally related to treatment / all	0 / 43	0 / 44	0 / 11
deaths causally related to treatment / all	0 / 5	0 / 5	0 / 1
Bronchospasm			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic respiratory disease			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			

subjects affected / exposed	6 / 8043 (0.07%)	6 / 8028 (0.07%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 6	0 / 6	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cough			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea exertional			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Emphysema			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eosinophilic pneumonia chronic			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epiglottic cyst			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	6 / 8043 (0.07%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrothorax			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Interstitial lung disease			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Laryngeal dysplasia			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal granuloma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung consolidation			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal polyp			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung disorder			

subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Mediastinal cyst			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal polyps			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal septum deviation			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive airways disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Oesophagobronchial fistula			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal pouch			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pickwickian syndrome			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			

subjects affected / exposed	13 / 8043 (0.16%)	8 / 8028 (0.10%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 14	0 / 8	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 0
Pleurisy			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	6 / 8043 (0.07%)	5 / 8028 (0.06%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 6	0 / 5	0 / 2
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 2
Pneumonitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	5 / 8043 (0.06%)	3 / 8028 (0.04%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Pulmonary arteriopathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	28 / 8043 (0.35%)	28 / 8028 (0.35%)	7 / 3144 (0.22%)
occurrences causally related to treatment / all	0 / 29	0 / 30	0 / 7
deaths causally related to treatment / all	0 / 7	0 / 9	0 / 0
Pulmonary fibrosis			

subjects affected / exposed	8 / 8043 (0.10%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 4	0 / 1	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mass			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	3 / 8043 (0.04%)	6 / 8028 (0.07%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 6	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 1
Pulmonary ossification			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary thrombosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Respiratory disorder			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			

subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	13 / 8043 (0.16%)	9 / 8028 (0.11%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 14	0 / 9	0 / 1
deaths causally related to treatment / all	0 / 7	0 / 6	0 / 1
Respiratory tract inflammation			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus polyp			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus polyp degeneration			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Throat irritation			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheal stenosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vocal cord disorder			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vocal cord polyp			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Alcohol abuse			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol withdrawal syndrome			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety disorder			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety disorder due to a general medical condition			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Completed suicide			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Compulsive hoarding			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	4 / 8043 (0.05%)	3 / 8028 (0.04%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	10 / 8043 (0.12%)	10 / 8028 (0.12%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 10	1 / 10	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphemia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysthymic disorder			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental disorder			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mood disorder due to a general medical condition			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Panic attack			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychogenic pain disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychogenic seizure			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood calcium decreased			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood cortisol increased			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood parathyroid hormone increased			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood pressure increased			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood urea increased			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulation time prolonged			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram QT prolonged			

subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram abnormal			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Grip strength decreased			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoglobin decreased			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart rate irregular			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
International normalised ratio decreased			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigation			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial necrosis marker increased			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Occult blood positive			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Residual urine volume increased			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight decreased			
subjects affected / exposed	1 / 8043 (0.01%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Abdominal wound dehiscence			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetabulum fracture			
subjects affected / exposed	0 / 8043 (0.00%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anastomotic leak			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Animal bite			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	13 / 8043 (0.16%)	19 / 8028 (0.24%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 15	0 / 23	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic injury			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Arterial injury			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial restenosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthropod bite			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical femur fracture			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back injury			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone contusion			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder injury			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone fissure			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve rupture			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical vertebral fracture			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chillblains			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clavicle fracture			
subjects affected / exposed	5 / 8043 (0.06%)	8 / 8028 (0.10%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 8	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Comminuted fracture			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Compression fracture			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	6 / 8043 (0.07%)	8 / 8028 (0.10%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 8	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Contusion			

subjects affected / exposed	5 / 8043 (0.06%)	15 / 8028 (0.19%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 18	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Craniocerebral injury			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Excoriation			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug dispensing error			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extradural haematoma			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Face injury			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	5 / 8043 (0.06%)	2 / 8028 (0.02%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			

subjects affected / exposed	29 / 8043 (0.36%)	62 / 8028 (0.77%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 29	0 / 64	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	44 / 8043 (0.55%)	40 / 8028 (0.50%)	8 / 3144 (0.25%)
occurrences causally related to treatment / all	1 / 49	0 / 41	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Fibula fracture			
subjects affected / exposed	11 / 8043 (0.14%)	10 / 8028 (0.12%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 11	0 / 10	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	5 / 8043 (0.06%)	9 / 8028 (0.11%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 5	0 / 9	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Forearm fracture			
subjects affected / exposed	1 / 8043 (0.01%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fractured ischium			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture displacement			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fractured sacrum			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gun shot wound			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hand fracture			
subjects affected / exposed	1 / 8043 (0.01%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	8 / 8043 (0.10%)	13 / 8028 (0.16%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 8	0 / 13	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Heat illness			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heat exhaustion			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heat stroke			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	55 / 8043 (0.68%)	104 / 8028 (1.30%)	6 / 3144 (0.19%)
occurrences causally related to treatment / all	0 / 56	0 / 105	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Humerus fracture			
subjects affected / exposed	28 / 8043 (0.35%)	51 / 8028 (0.64%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 29	0 / 51	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			

subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Jaw fracture			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	6 / 8043 (0.07%)	6 / 8028 (0.07%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 7	0 / 6	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
subjects affected / exposed	3 / 8043 (0.04%)	4 / 8028 (0.05%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	6 / 8043 (0.07%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 6	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament rupture			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb crushing injury			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament sprain			

subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb traumatic amputation			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	13 / 8043 (0.16%)	25 / 8028 (0.31%)	6 / 3144 (0.19%)
occurrences causally related to treatment / all	0 / 17	0 / 27	0 / 7
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Meniscus injury			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth injury			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	4 / 8043 (0.05%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Muscle injury			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle rupture			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle strain			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve root injury lumbar			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella fracture			
subjects affected / exposed	8 / 8043 (0.10%)	11 / 8028 (0.14%)	5 / 3144 (0.16%)
occurrences causally related to treatment / all	0 / 9	0 / 11	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perineal injury			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Post procedural discomfort			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural fistula			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural inflammation			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural swelling			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural oedema			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic neck syndrome			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative adhesion			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative hernia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative ileus			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative respiratory failure			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural complication			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural nausea			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pain			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pubis fracture			

subjects affected / exposed	11 / 8043 (0.14%)	7 / 8028 (0.09%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 12	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary contusion			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	66 / 8043 (0.82%)	77 / 8028 (0.96%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 68	0 / 79	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	7 / 8043 (0.09%)	10 / 8028 (0.12%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 9	0 / 10	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Scapula fracture			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scar			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin abrasion			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin injury			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin wound			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fractured base			
subjects affected / exposed	4 / 8043 (0.05%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue injury			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal column injury			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord injury cervical			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Spinal fracture			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic rupture			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sternal fracture			
subjects affected / exposed	3 / 8043 (0.04%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sternal injury			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous haematoma			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Subdural haematoma			
subjects affected / exposed	6 / 8043 (0.07%)	5 / 8028 (0.06%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 6	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Synovial rupture			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon injury			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	12 / 8043 (0.15%)	23 / 8028 (0.29%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 13	0 / 28	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	13 / 8043 (0.16%)	22 / 8028 (0.27%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 13	0 / 22	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic haemothorax			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic shock			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	15 / 8043 (0.19%)	28 / 8028 (0.35%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 17	0 / 28	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulnar nerve injury			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	2 / 8043 (0.02%)	6 / 8028 (0.07%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 7	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular injury			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular pseudoaneurysm			
subjects affected / exposed	5 / 8043 (0.06%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound haemorrhage			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	6 / 8043 (0.07%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 6	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Atrial septal defect			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital bronchiectasis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital cystic kidney disease			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertrophic cardiomyopathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Exomphalos			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroglossal cyst			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	55 / 8043 (0.68%)	55 / 8028 (0.69%)	17 / 3144 (0.54%)
occurrences causally related to treatment / all	2 / 57	0 / 59	0 / 17
deaths causally related to treatment / all	0 / 16	0 / 14	0 / 8
Adams-Stokes syndrome			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	39 / 8043 (0.48%)	41 / 8028 (0.51%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 44	0 / 44	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	34 / 8043 (0.42%)	34 / 8028 (0.42%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 43	1 / 37	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Aortic valve disease			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	5 / 8043 (0.06%)	6 / 8028 (0.07%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 7	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Arrhythmia supraventricular			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriosclerosis coronary artery			
subjects affected / exposed	4 / 8043 (0.05%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	73 / 8043 (0.91%)	80 / 8028 (1.00%)	17 / 3144 (0.54%)
occurrences causally related to treatment / all	0 / 83	0 / 97	0 / 23
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 0
Atrial tachycardia			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			

subjects affected / exposed	4 / 8043 (0.05%)	6 / 8028 (0.07%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial flutter			
subjects affected / exposed	8 / 8043 (0.10%)	6 / 8028 (0.07%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 9	1 / 6	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block first degree			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	5 / 8043 (0.06%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular dissociation			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradyarrhythmia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	10 / 8043 (0.12%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 10	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bundle branch block bilateral			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bundle branch block left			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bundle branch block right			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute coronary syndrome			
subjects affected / exposed	10 / 8043 (0.12%)	9 / 8028 (0.11%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 10	0 / 10	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	9 / 8043 (0.11%)	13 / 8028 (0.16%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 10	0 / 13	0 / 2
deaths causally related to treatment / all	0 / 6	0 / 12	0 / 2
Cardiac disorder			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiac failure			
subjects affected / exposed	35 / 8043 (0.44%)	41 / 8028 (0.51%)	7 / 3144 (0.22%)
occurrences causally related to treatment / all	0 / 38	0 / 44	0 / 7
deaths causally related to treatment / all	0 / 9	0 / 9	0 / 5
Cardiac failure acute			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Cardiac failure chronic			
subjects affected / exposed	7 / 8043 (0.09%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 9	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac failure congestive			

subjects affected / exposed	37 / 8043 (0.46%)	35 / 8028 (0.44%)	10 / 3144 (0.32%)
occurrences causally related to treatment / all	0 / 38	2 / 36	0 / 10
deaths causally related to treatment / all	0 / 8	0 / 5	0 / 2
Cardiac tamponade			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiac valve disease			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac ventricular thrombosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	11 / 8043 (0.14%)	14 / 8028 (0.17%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 11	0 / 14	0 / 4
deaths causally related to treatment / all	0 / 11	0 / 11	0 / 4
Cardiogenic shock			
subjects affected / exposed	5 / 8043 (0.06%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 5	0 / 3	0 / 0
Cardiomyopathy			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiopulmonary failure			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Cardiovascular disorder			

subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiovascular insufficiency			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congestive cardiomyopathy			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Coronary artery disease			
subjects affected / exposed	31 / 8043 (0.39%)	25 / 8028 (0.31%)	7 / 3144 (0.22%)
occurrences causally related to treatment / all	0 / 34	1 / 28	0 / 7
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cor pulmonale acute			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery insufficiency			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Coronary artery occlusion			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery perforation			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Coronary artery stenosis			

subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytotoxic cardiomyopathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extrasystoles			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart valve incompetence			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive cardiomyopathy			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cardiomyopathy			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Microvascular coronary artery disease			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve disease			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Mitral valve incompetence			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Mitral valve stenosis			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	47 / 8043 (0.58%)	48 / 8028 (0.60%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 50	0 / 51	0 / 4
deaths causally related to treatment / all	0 / 16	0 / 19	0 / 2
Myocardial ischaemia			
subjects affected / exposed	19 / 8043 (0.24%)	12 / 8028 (0.15%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 21	0 / 12	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 0
Myocarditis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pericardial haemorrhage			

subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Postinfarction angina			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prinzmetal angina			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sinoatrial block			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus bradycardia			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pericarditis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus node dysfunction			
subjects affected / exposed	8 / 8043 (0.10%)	9 / 8028 (0.11%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 8	0 / 9	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress cardiomyopathy			

subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular extrasystoles			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	4 / 8043 (0.05%)	4 / 8028 (0.05%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	1 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachyarrhythmia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia paroxysmal			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tricuspid valve incompetence			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ventricular dysfunction			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular extrasystoles			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Amnesia			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amyotrophic lateral sclerosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apallic syndrome			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphasia			

subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ataxia			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Balance disorder			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal ganglia haemorrhage			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Basal ganglia infarction			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain injury			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Brain oedema			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain stem infarction			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain stem stroke			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid arteriosclerosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery aneurysm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery disease			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery occlusion			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			
subjects affected / exposed	4 / 8043 (0.05%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery thrombosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid sinus syndrome			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			

subjects affected / exposed	9 / 8043 (0.11%)	5 / 8028 (0.06%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 11	0 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar ischaemia			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar infarction			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral arteriosclerosis			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral artery embolism			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral circulatory failure			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haematoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	1 / 8043 (0.01%)	9 / 8028 (0.11%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 9	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 5	0 / 2
Cerebral infarction			

subjects affected / exposed	31 / 8043 (0.39%)	18 / 8028 (0.22%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	2 / 32	0 / 18	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Cerebral ischaemia			
subjects affected / exposed	5 / 8043 (0.06%)	8 / 8028 (0.10%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 9	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral thrombosis			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral venous thrombosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	68 / 8043 (0.85%)	42 / 8028 (0.52%)	8 / 3144 (0.25%)
occurrences causally related to treatment / all	2 / 68	1 / 43	0 / 8
deaths causally related to treatment / all	0 / 9	0 / 8	0 / 2
Cerebrovascular disorder			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Cerebrovascular insufficiency			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical myelopathy			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical radiculopathy			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 8043 (0.00%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Complex partial seizures			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cranial nerve disorder			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia			
subjects affected / exposed	2 / 8043 (0.02%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Dementia Alzheimer's type			
subjects affected / exposed	5 / 8043 (0.06%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Depressed level of consciousness			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic neuropathy			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	8 / 8043 (0.10%)	7 / 8028 (0.09%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	3 / 10	0 / 7	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyslalia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolitic cerebral infarction			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 8043 (0.00%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	6 / 8043 (0.07%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 7	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Frontotemporal dementia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Guillain-Barre syndrome			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Haemorrhage intracranial			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	10 / 8043 (0.12%)	6 / 8028 (0.07%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 10	0 / 6	0 / 4
deaths causally related to treatment / all	0 / 8	0 / 2	0 / 4
Headache			
subjects affected / exposed	5 / 8043 (0.06%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	1 / 5	1 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegia			
subjects affected / exposed	4 / 8043 (0.05%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic encephalopathy			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			

subjects affected / exposed	0 / 8043 (0.00%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive encephalopathy			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertonia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemic coma			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemic unconsciousness			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotonia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
IVth nerve paralysis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
IIIrd nerve paralysis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			

subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Intracranial haematoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial venous sinus thrombosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cerebral infarction			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic neuropathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	39 / 8043 (0.48%)	40 / 8028 (0.50%)	21 / 3144 (0.67%)
occurrences causally related to treatment / all	0 / 40	0 / 41	0 / 22
deaths causally related to treatment / all	0 / 3	0 / 4	0 / 1
Lacunar infarction			
subjects affected / exposed	4 / 8043 (0.05%)	8 / 8028 (0.10%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 9	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	6 / 8043 (0.07%)	8 / 8028 (0.10%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 6	0 / 8	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar radiculopathy			

subjects affected / exposed	4 / 8043 (0.05%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Memory impairment			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningorrhagia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Morton's neuralgia			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Motor neurone disease			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Myasthenia gravis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve root compression			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve compression			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuritis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Normal pressure hydrocephalus			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraparesis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parkinson's disease			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parkinsonism			

subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral nerve lesion			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensorimotor neuropathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyneuropathy			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post herpetic neuralgia			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	4 / 8043 (0.05%)	4 / 8028 (0.05%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiculopathy			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radicular syndrome			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ruptured cerebral aneurysm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sciatica			
subjects affected / exposed	3 / 8043 (0.04%)	6 / 8028 (0.07%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 7	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sedation			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	5 / 8043 (0.06%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Senile dementia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Sensory disturbance			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Slow speech			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	3 / 8043 (0.04%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Syncope			
subjects affected / exposed	31 / 8043 (0.39%)	20 / 8028 (0.25%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 33	0 / 20	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Thalamus haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic stroke			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Transient global amnesia			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			

subjects affected / exposed	31 / 8043 (0.39%)	35 / 8028 (0.44%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	2 / 33	0 / 38	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Trigeminal neuralgia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIIth nerve paralysis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular dementia			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular encephalopathy			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebral artery stenosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebrobasilar insufficiency			
subjects affected / exposed	2 / 8043 (0.02%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White matter lesion			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	16 / 8043 (0.20%)	21 / 8028 (0.26%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 17	0 / 22	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia megaloblastic			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia vitamin B12 deficiency			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aplastic anaemia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Coagulopathy			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune haemolytic anaemia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic diathesis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic disorder			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypochromic anaemia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune thrombocytopenic purpura			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	4 / 8043 (0.05%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Lymphadenopathy mediastinal			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Normochromic normocytic anaemia			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polycythaemia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pernicious anaemia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deafness neurosensory			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
External ear disorder			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inner ear disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniere's disease			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurosensory hypoacusis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden hearing loss			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otosclerosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tinnitus			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo			
subjects affected / exposed	15 / 8043 (0.19%)	5 / 8028 (0.06%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	1 / 16	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tympanic membrane perforation			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional			
subjects affected / exposed	5 / 8043 (0.06%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Age-related macular degeneration			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amaurosis fugax			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angle closure glaucoma			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blindness			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blindness unilateral			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract nuclear			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			

subjects affected / exposed	98 / 8043 (1.22%)	79 / 8028 (0.98%)	12 / 3144 (0.38%)
occurrences causally related to treatment / all	0 / 131	0 / 108	0 / 16
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chalazion			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choroiditis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Corneal opacity			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystoid macular oedema			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dacryostenosis acquired			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diplopia			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Entropion			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excessive eye blinking			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eyelid ptosis			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glaucoma			
subjects affected / exposed	8 / 8043 (0.10%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 9	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iritis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratitis interstitial			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratopathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lacrimal disorder			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lens disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular degeneration			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular fibrosis			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular hole			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Maculopathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myopia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neovascular age-related macular degeneration			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic atrophy			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic ischaemic neuropathy			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Posterior capsule opacification			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal artery embolism			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal degeneration			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			
subjects affected / exposed	2 / 8043 (0.02%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal dystrophy			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vein occlusion			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vein thrombosis			
subjects affected / exposed	1 / 8043 (0.01%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinopathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Trichiasis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcerative keratitis			
subjects affected / exposed	0 / 8043 (0.00%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vision blurred			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual acuity reduced			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual impairment			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitreous haemorrhage			

subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Corneal scar			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flat anterior chamber of eye			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Open angle glaucoma			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ciliary body disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal distension			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia obstructive			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	9 / 8043 (0.11%)	9 / 8028 (0.11%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 9	0 / 9	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	7 / 8043 (0.09%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	1 / 7	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Anal fistula			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fissure			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal inflammation			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal stenosis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Barrett's oesophagus			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic gastritis			
subjects affected / exposed	7 / 8043 (0.09%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 7	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Change of bowel habit			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	8 / 8043 (0.10%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 8	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	5 / 8043 (0.06%)	7 / 8028 (0.09%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 7	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Colitis ulcerative			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis microscopic			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			

subjects affected / exposed	9 / 8043 (0.11%)	10 / 8028 (0.12%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 9	1 / 10	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	12 / 8043 (0.15%)	8 / 8028 (0.10%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 14	0 / 9	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticular perforation			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Diverticulum			
subjects affected / exposed	9 / 8043 (0.11%)	9 / 8028 (0.11%)	5 / 3144 (0.16%)
occurrences causally related to treatment / all	0 / 9	0 / 9	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis intestinal haemorrhagic			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			
subjects affected / exposed	7 / 8043 (0.09%)	3 / 8028 (0.04%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 7	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal haemorrhagic			

subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum oesophageal			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dolichocolon acquired			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal perforation			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Duodenal ulcer			
subjects affected / exposed	5 / 8043 (0.06%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer perforation			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Duodenitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysbacteriosis			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocoele			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovesical fistula			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erosive oesophagitis			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecal incontinence			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 8043 (0.00%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal mass			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal prolapse			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia incarcerated			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Functional gastrointestinal disorder			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food poisoning			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric antral vascular ectasia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			
subjects affected / exposed	5 / 8043 (0.06%)	7 / 8028 (0.09%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 6	0 / 7	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Gastric ulcer haemorrhage			
subjects affected / exposed	3 / 8043 (0.04%)	4 / 8028 (0.05%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	1 / 3	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer perforation			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Gastritis			
subjects affected / exposed	19 / 8043 (0.24%)	10 / 8028 (0.12%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 19	1 / 11	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroduodenitis			

subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal angiodysplasia			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	6 / 8043 (0.07%)	7 / 8028 (0.09%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 6	0 / 7	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Gastrointestinal inflammation			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal motility disorder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal necrosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Gastrointestinal obstruction			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal ulcer haemorrhage			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	8 / 8043 (0.10%)	10 / 8028 (0.12%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	1 / 8	0 / 10	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	11 / 8043 (0.14%)	10 / 8028 (0.12%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 11	0 / 10	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal ulcer			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids thrombosed			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hernial eventration			

subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	7 / 8043 (0.09%)	7 / 8028 (0.09%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 7	0 / 8	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ileus paralytic			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Inguinal hernia			
subjects affected / exposed	7 / 8043 (0.09%)	11 / 8028 (0.14%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 7	0 / 11	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal ischaemia			
subjects affected / exposed	3 / 8043 (0.04%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal mass			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	11 / 8043 (0.14%)	11 / 8028 (0.14%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 12	0 / 12	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 1
Intestinal perforation			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Intestinal prolapse			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal polyp			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Irritable bowel syndrome			
subjects affected / exposed	3 / 8043 (0.04%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischiorectal hernia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			

subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Large intestine polyp			
subjects affected / exposed	6 / 8043 (0.07%)	10 / 8028 (0.12%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 6	1 / 10	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar hernia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mallory-Weiss syndrome			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mechanical ileus			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesenteric artery embolism			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth cyst			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth ulceration			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal achalasia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal fistula			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal pain			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal hypomotility			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			

subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal varices haemorrhage			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	4 / 8043 (0.05%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis ulcerative			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral pain			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic cyst			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic mass			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pancreatic pseudocyst			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			

subjects affected / exposed	8 / 8043 (0.10%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 8	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	8 / 8043 (0.10%)	5 / 8028 (0.06%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 8	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pancreatitis chronic			
subjects affected / exposed	4 / 8043 (0.05%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis necrotising			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Peptic ulcer			
subjects affected / exposed	3 / 8043 (0.04%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peptic ulcer perforation			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peptic ulcer haemorrhage			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngo-oesophageal diverticulum			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			

subjects affected / exposed	6 / 8043 (0.07%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Rectal polyp			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal prolapse			
subjects affected / exposed	4 / 8043 (0.05%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salivary gland calculus			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	4 / 8043 (0.05%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic artery aneurysm			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomach mass			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis mesenteric vessel			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Subileus			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toothache			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			
subjects affected / exposed	3 / 8043 (0.04%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haematoma			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	4 / 8043 (0.05%)	10 / 8028 (0.12%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 10	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 3	0 / 0
Volvulus			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	3 / 8043 (0.04%)	6 / 8028 (0.07%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Gastric polyps			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bile duct stenosis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary colic			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stone			
subjects affected / exposed	9 / 8043 (0.11%)	3 / 8028 (0.04%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 10	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary fistula			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis acute			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			

subjects affected / exposed	20 / 8043 (0.25%)	15 / 8028 (0.19%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 20	0 / 15	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	7 / 8043 (0.09%)	15 / 8028 (0.19%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 7	0 / 15	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cholecystitis chronic			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	34 / 8043 (0.42%)	34 / 8028 (0.42%)	7 / 3144 (0.22%)
occurrences causally related to treatment / all	0 / 34	0 / 38	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic hepatitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder disorder			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder polyp			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cirrhosis			
subjects affected / exposed	4 / 8043 (0.05%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatic cyst			

subjects affected / exposed	1 / 8043 (0.01%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic steatosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis cholestatic			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatorenal failure			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Jaundice			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Liver disorder			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-alcoholic steatohepatitis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Post cholecystectomy syndrome			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocholecystitis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perforation bile duct			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal vein thrombosis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute generalised exanthematous pustulosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angioedema			

subjects affected / exposed	2 / 8043 (0.02%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrophoderma of Pasini and Pierini			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blister			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decubitus ulcer			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Dermal cyst			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis allergic			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis contact			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis atopic			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatomyositis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic foot			
subjects affected / exposed	1 / 8043 (0.01%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema asteatotic			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema multiforme			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand dermatitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Henoch-Schonlein purpura			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkeratosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity vasculitis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ingrowing nail			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lentigo			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukoplakia			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lichen sclerosus			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurodermatitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pemphigoid			

subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pemphigus			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pruritus generalised			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoriasis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyoderma gangrenosum			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash erythematous			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash generalised			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			

subjects affected / exposed	4 / 8043 (0.05%)	6 / 8028 (0.07%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Skin wrinkling			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	6 / 8043 (0.07%)	6 / 8028 (0.07%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 6	0 / 6	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Acute prerenal failure			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Azotaemia			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Bladder cyst			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder diverticulum			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder irritation			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder perforation			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder prolapse			
subjects affected / exposed	3 / 8043 (0.04%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus bladder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus ureteric			
subjects affected / exposed	1 / 8043 (0.01%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urethral			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic kidney disease			
subjects affected / exposed	5 / 8043 (0.06%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 5	0 / 1	0 / 0
deaths causally related to treatment / all	1 / 3	0 / 0	0 / 0
Glomerulonephritis			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cystitis haemorrhagic			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis membranous			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis rapidly progressive			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	4 / 8043 (0.05%)	5 / 8028 (0.06%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertonic bladder			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic syndrome			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			

subjects affected / exposed	4 / 8043 (0.05%)	10 / 8028 (0.12%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 10	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oliguria			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pollakiuria			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal artery stenosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	2 / 8043 (0.02%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	3 / 8043 (0.04%)	4 / 8028 (0.05%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 3	0 / 1
Renal impairment			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal mass			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal tubular disorder			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scleroderma renal crisis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress urinary incontinence			
subjects affected / exposed	3 / 8043 (0.04%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubulointerstitial nephritis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric stenosis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral caruncle			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral polyp			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral stenosis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder polyp			

subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary incontinence			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	1 / 8043 (0.01%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adrenal haemorrhage			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune thyroiditis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Goitre			
subjects affected / exposed	2 / 8043 (0.02%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperadrenalism			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperparathyroidism			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperparathyroidism primary			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypothyroidism			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Primary hypothyroidism			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Secondary hyperthyroidism			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cyst			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroiditis subacute			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid mass			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	4 / 8043 (0.05%)	6 / 8028 (0.07%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	12 / 8043 (0.15%)	8 / 8028 (0.10%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 13	0 / 10	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis reactive			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atlantoaxial instability			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Axillary mass			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	20 / 8043 (0.25%)	22 / 8028 (0.27%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 20	0 / 22	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone loss			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	4 / 8043 (0.05%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondropathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Connective tissue disorder			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dupuytren's contracture			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Costochondritis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eosinophilic fasciitis			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facet joint syndrome			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	12 / 8043 (0.15%)	10 / 8028 (0.12%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 14	0 / 11	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture delayed union			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture malunion			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture pain			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	0 / 8043 (0.00%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc disorder			

subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	12 / 8043 (0.15%)	10 / 8028 (0.12%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 12	0 / 10	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc space narrowing			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaw cyst			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint adhesion			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint contracture			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint stiffness			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint range of motion decreased			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint swelling			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Knee deformity			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	9 / 8043 (0.11%)	6 / 8028 (0.07%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 9	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mobility decreased			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Monarthrititis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Morphoea			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasms			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			

subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	7 / 8043 (0.09%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 7	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nodal osteoarthritis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	135 / 8043 (1.68%)	115 / 8028 (1.43%)	12 / 3144 (0.38%)
occurrences causally related to treatment / all	0 / 154	0 / 132	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteochondritis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteochondrosis			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteosclerosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	9 / 8043 (0.11%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	2 / 10	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periarthritis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periostitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plantar fasciitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polymyalgia rheumatica			
subjects affected / exposed	6 / 8043 (0.07%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	18 / 8043 (0.22%)	11 / 8028 (0.14%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 18	0 / 12	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			

subjects affected / exposed	5 / 8043 (0.06%)	7 / 8028 (0.09%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 5	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scleroderma			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scoliosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sjogren's syndrome			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue necrosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal column stenosis			
subjects affected / exposed	15 / 8043 (0.19%)	17 / 8028 (0.21%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 15	0 / 17	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	3 / 8043 (0.04%)	7 / 8028 (0.09%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylitis			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondyloarthropathy			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			
subjects affected / exposed	5 / 8043 (0.06%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial cyst			
subjects affected / exposed	6 / 8043 (0.07%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic lupus erythematosus			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendonitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tenosynovitis stenosans			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Trigger finger			

subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulnocarpal abutment syndrome			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal sepsis			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Abdominal wall abscess			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess limb			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess neck			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute sinusitis			

subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amoebic colitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	18 / 8043 (0.22%)	12 / 8028 (0.15%)	6 / 3144 (0.19%)
occurrences causally related to treatment / all	0 / 18	0 / 12	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Beta haemolytic streptococcal infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	15 / 8043 (0.19%)	14 / 8028 (0.17%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 15	0 / 15	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	18 / 8043 (0.22%)	17 / 8028 (0.21%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 19	0 / 18	0 / 0
deaths causally related to treatment / all	0 / 7	0 / 5	0 / 0
Burn infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carbuncle			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	15 / 8043 (0.19%)	16 / 8028 (0.20%)	3 / 3144 (0.10%)
occurrences causally related to treatment / all	0 / 17	0 / 20	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system viral infection			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chlamydial infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis infective			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic sinusitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cutaneous tuberculosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	4 / 8043 (0.05%)	8 / 8028 (0.10%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 4	1 / 8	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus gastrointestinal infection			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dacryocystitis			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	2 / 8043 (0.02%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental fistula			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic gangrene			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			

subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	25 / 8043 (0.31%)	20 / 8028 (0.25%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 27	0 / 22	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Dysentery			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endophthalmitis			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis infectious			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterobacter pneumonia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	6 / 8043 (0.07%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema migrans			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder empyema			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gangrene			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Gastritis viral			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	34 / 8043 (0.42%)	26 / 8028 (0.32%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 34	0 / 27	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis clostridial			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometritis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epstein-Barr virus infection			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extradural abscess			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis intestinal haemorrhagic			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital candidiasis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Helicobacter gastritis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis A			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Helicobacter infection			

subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis E			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes simplex encephalitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	5 / 8043 (0.06%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster infection neurological			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incision site infection			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected bites			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected dermal cyst			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected varicose vein			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of bronchiectasis			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	5 / 8043 (0.06%)	7 / 8028 (0.09%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 5	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal fistula infection			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratitis bacterial			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Labyrinthitis			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella bacteraemia			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lobar pneumonia			
subjects affected / exposed	11 / 8043 (0.14%)	12 / 8028 (0.15%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 11	0 / 12	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 0
Localised infection			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	13 / 8043 (0.16%)	9 / 8028 (0.11%)	5 / 3144 (0.16%)
occurrences causally related to treatment / all	0 / 13	0 / 9	0 / 6
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Lower respiratory tract infection bacterial			

subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lyme disease			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	2 / 8043 (0.02%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaria			
subjects affected / exposed	3 / 8043 (0.04%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mediastinitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Meningitis bacterial			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic sepsis			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurosyphilis			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	1 / 8043 (0.01%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic abscess			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parotitis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic sepsis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	7 / 8043 (0.09%)	5 / 8028 (0.06%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 7	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 4	0 / 1	0 / 1
Peritonsillar abscess			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngotonsillitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	117 / 8043 (1.45%)	116 / 8028 (1.44%)	31 / 3144 (0.99%)
occurrences causally related to treatment / all	0 / 134	0 / 121	0 / 32
deaths causally related to treatment / all	0 / 23	0 / 23	0 / 7
Pneumonia bacterial			
subjects affected / exposed	3 / 8043 (0.04%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumonia mycoplasmal			

subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia necrotising			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	2 / 8043 (0.02%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	3 / 8043 (0.04%)	5 / 8028 (0.06%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomembranous colitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal bacteraemia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary echinococcosis			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary sepsis			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulmonary tuberculosis			
subjects affected / exposed	3 / 8043 (0.04%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelocystitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	4 / 8043 (0.05%)	7 / 8028 (0.09%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 8	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	5 / 8043 (0.06%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis chronic			
subjects affected / exposed	3 / 8043 (0.04%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyometra			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyonephrosis			

subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal abscess			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonellosis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	23 / 8043 (0.29%)	18 / 8028 (0.22%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 24	0 / 19	0 / 2
deaths causally related to treatment / all	0 / 14	0 / 10	0 / 0
Septic shock			
subjects affected / exposed	12 / 8043 (0.15%)	7 / 8028 (0.09%)	6 / 3144 (0.19%)
occurrences causally related to treatment / all	0 / 12	0 / 7	0 / 6
deaths causally related to treatment / all	0 / 10	0 / 5	0 / 4
Sialoadenitis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinobronchitis			

subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 8043 (0.00%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal skin infection			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site abscess			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 8043 (0.00%)	4 / 8028 (0.05%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdiaphragmatic abscess			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tick-borne fever			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Tooth infection			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	2 / 8043 (0.02%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	54 / 8043 (0.67%)	49 / 8028 (0.61%)	16 / 3144 (0.51%)
occurrences causally related to treatment / all	1 / 58	1 / 59	1 / 16
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection pseudomonal			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	4 / 8043 (0.05%)	4 / 8028 (0.05%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Vestibular neuronitis			
subjects affected / exposed	1 / 8043 (0.01%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	3 / 8043 (0.04%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral labyrinthitis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	2 / 8043 (0.02%)	7 / 8028 (0.09%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 7	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound sepsis			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Wound infection staphylococcal			

subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal abscess			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis bacterial			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	13 / 8043 (0.16%)	7 / 8028 (0.09%)	2 / 3144 (0.06%)
occurrences causally related to treatment / all	0 / 13	0 / 7	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Diabetes mellitus			
subjects affected / exposed	5 / 8043 (0.06%)	10 / 8028 (0.12%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 10	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Diabetes mellitus inadequate control			

subjects affected / exposed	8 / 8043 (0.10%)	9 / 8028 (0.11%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 9	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	4 / 8043 (0.05%)	2 / 8028 (0.02%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic metabolic decompensation			
subjects affected / exposed	0 / 8043 (0.00%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	3 / 8043 (0.04%)	2 / 8028 (0.02%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 8043 (0.00%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	1 / 8043 (0.01%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hyperosmolar state			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	8 / 8043 (0.10%)	6 / 8028 (0.07%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 9	0 / 6	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hypokalaemia			
subjects affected / exposed	3 / 8043 (0.04%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	8 / 8043 (0.10%)	14 / 8028 (0.17%)	4 / 3144 (0.13%)
occurrences causally related to treatment / all	0 / 9	0 / 15	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophagia			
subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ketoacidosis			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	2 / 8043 (0.02%)	1 / 8028 (0.01%)	1 / 3144 (0.03%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metabolic acidosis			

subjects affected / exposed	1 / 8043 (0.01%)	0 / 8028 (0.00%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic disorder			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 8043 (0.00%)	1 / 8028 (0.01%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	2 / 8043 (0.02%)	3 / 8028 (0.04%)	0 / 3144 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Second Extension: Odanacatib 50 mg OW (Placebo)		
Total subjects affected by serious adverse events			
subjects affected / exposed	376 / 2309 (16.28%)		
number of deaths (all causes)	39		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Abdominal neoplasm			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Acute leukaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute myeloid leukaemia			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma gastric			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma of appendix			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma of colon			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma of the cervix			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angiosarcoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Astrocytoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
B-cell lymphoma			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Basal cell carcinoma			
subjects affected / exposed	8 / 2309 (0.35%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
Benign gastric neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Benign breast neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Benign lung neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Benign muscle neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Benign neoplasm of bladder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Benign neoplasm of thyroid gland			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Benign neoplasm of skin			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Benign salivary gland neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Benign vulval neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bile duct cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bone cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bone neoplasm			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Borderline mucinous tumour of ovary			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bowen's disease			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Brain cancer metastatic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer			
subjects affected / exposed	9 / 2309 (0.39%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
Brain neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer in situ			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer recurrent			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Breast cancer metastatic			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer stage III			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchial carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchioloalveolar carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carcinoid tumour of the stomach			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carcinoma in situ of skin			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac myxoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebellar tumour			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebellopontine angle tumour			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervix cancer metastatic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervix carcinoma			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cervix carcinoma recurrent			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervix carcinoma stage II			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholangiocarcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chondroma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Choroid melanoma			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic lymphocytic leukaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colon adenoma			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Clear cell endometrial carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colon cancer			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Colon cancer metastatic			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Colon neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colorectal cancer recurrent			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diffuse large B-cell lymphoma stage IV			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ductal adenocarcinoma of pancreas			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenal neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dysplastic naevus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endometrial adenocarcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endometrial cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Essential thrombocythaemia			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fallopian tube cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Female reproductive neoplasm			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fibroadenoma of breast				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fibromatosis				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fibroma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Follicle centre lymphoma, follicular grade I, II, III stage II				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gallbladder adenocarcinoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gallbladder cancer				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastric cancer				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastric cancer stage IV				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal stromal tumour			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal tract adenoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gingival cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glioblastoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glioblastoma multiforme			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Glomus tumour				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemangioma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemangioma of bone				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatic cancer				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Hepatic neoplasm				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatocellular carcinoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Inflammatory carcinoma of the breast				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intraductal papilloma of breast				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intraductal proliferative breast lesion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intraocular melanoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Invasive breast carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Invasive ductal breast carcinoma			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Invasive lobular breast carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Kaposi's sarcoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Keratoacanthoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leiomyoma			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Laryngeal squamous cell carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leiomyosarcoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lentigo maligna			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Leukaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lip and/or oral cavity cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lip squamous cell carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lipoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Liposarcoma			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lobular breast carcinoma in situ			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma stage I			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma stage IV			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung cancer metastatic			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung carcinoma cell type unspecified stage IV			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung neoplasm malignant			

subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Lymphangioma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lymphoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lymphoproliferative disorder				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant melanoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant melanoma in situ				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Malignant neoplasm of ampulla of Vater				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant neoplasm of eyelid				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant neoplasm of renal pelvis				

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant neoplasm of unknown primary site				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant neoplasm progression				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant peritoneal neoplasm				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mantle cell lymphoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Medullary thyroid cancer				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Melanocytic naevus				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Melanoma recurrent				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mesothelioma				

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningioma				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mesothelioma malignant				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metaplastic breast carcinoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to central nervous system				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to liver				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to lung				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to lymph nodes				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Metastases to peritoneum				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to pleura			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to skin			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastasis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic bronchial carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic gastric cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic malignant melanoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic salivary gland cancer			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastatic uterine cancer				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mixed adenoneuroendocrine carcinoma				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mucinous breast carcinoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myelodysplastic syndrome				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mycosis fungoides				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myelodysplastic syndrome transformation				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myeloproliferative disorder				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nasal cavity cancer				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nasal neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nasopharyngeal cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neoplasm malignant			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Neuroendocrine carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neuroendocrine carcinoma metastatic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neuroendocrine tumour			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-Hodgkin's lymphoma			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-small cell lung cancer				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-small cell lung cancer metastatic				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-small cell lung cancer stage IV				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal adenocarcinoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal carcinoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal squamous cell carcinoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oligodendroglioma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oropharyngeal cancer				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteosarcoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian adenoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian cancer metastatic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian epithelial cancer stage I			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic carcinoma			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatic carcinoma metastatic				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatic carcinoma stage IV				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatic neoplasm				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Papillary serous endometrial carcinoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Papillary thyroid cancer				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Papilloma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Parathyroid tumour benign				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peritoneal mesothelioma malignant				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pharyngeal cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Plasma cell myeloma			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Plasmacytoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleural neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Primary myelofibrosis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyogenic granuloma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal adenocarcinoma			

subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Rectal adenoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal cancer				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal neoplasm				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectosigmoid cancer				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Refractory anaemia with an excess of blasts				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Refractory cytopenia with unilineage dysplasia				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal cancer				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal cell carcinoma				

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal cell carcinoma stage II			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal oncocytoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retroperitoneal cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Salivary gland cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sarcoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Schwannoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Seborrhoeic keratosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small cell lung cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small cell lung cancer limited stage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Soft tissue neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal cord neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Splenic marginal zone lymphoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of lung			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of skin				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of the cervix				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of the oral cavity				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of the tongue				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Superficial spreading melanoma stage unspecified				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
T-cell lymphoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thymoma malignant				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Thyroid adenoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thyroid cancer				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Thyroid cancer metastatic				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thyroid neoplasm				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tongue neoplasm malignant stage unspecified				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tonsil cancer				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Transitional cell cancer of the renal pelvis and ureter				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Transitional cell carcinoma				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Ureteric cancer				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine leiomyoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine neoplasm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vulval cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vulval cancer stage 0			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to bone			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral cancer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of the vagina			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic aneurysm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic aneurysm rupture			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Aortic arteriosclerosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic dissection			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Arterial disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic stenosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arterial stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arteriosclerosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bleeding varicose vein			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood pressure fluctuation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Circulatory collapse			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Deep vein thrombosis			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Distributive shock			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Essential hypertension			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Iliac artery embolism			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Extremity necrosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femoral artery occlusion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hot flush			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertension			
subjects affected / exposed	4 / 2309 (0.17%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Hypertensive crisis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hypertensive emergency			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hypovolaemic shock			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Iliac artery occlusion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infarction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intermittent claudication			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant hypertension			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Necrosis ischaemic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Orthostatic hypotension			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral artery stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral artery thrombosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral ischaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral circulatory failure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral vascular disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral venous disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Phlebitis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Shock haemorrhagic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subgaleal haematoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Temporal arteritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombophlebitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombophlebitis superficial			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Varicose ulceration			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vasculitis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Varicose vein			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vena cava thrombosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis limb			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Accidental death			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adverse event			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asthenia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Capsular contracture associated with breast implant			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest discomfort			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	4 / 2309 (0.17%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death			
subjects affected / exposed	4 / 2309 (0.17%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 4		
Device adhesion issue			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device breakage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device damage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device dislocation			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device malfunction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device material issue			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Drug intolerance			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Drug withdrawal syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Facial pain			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fatigue			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General symptom			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hernia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ill-defined disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Impaired healing			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Implant site reaction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malaise			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Medical device complication			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multi-organ disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multi-organ failure			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nodule			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-cardiac chest pain			
subjects affected / exposed	4 / 2309 (0.17%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Oedema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oedema peripheral			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oral administration complication			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral swelling			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Soft tissue inflammation			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Strangulated hernia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sudden death			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Systemic inflammatory response syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Organ failure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaphylactic shock			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Drug hypersensitivity			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypersensitivity			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sarcoidosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Social circumstances			
Immobile			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Adnexal torsion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adnexa uteri mass			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anisomastia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast mass			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Cervical dysplasia				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cervical polyp				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colpocoele				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystocoele				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dysfunctional uterine bleeding				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endometrial hyperplasia				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Genital labial adhesions				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hydrometra				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Metrorrhagia				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian cyst			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Pelvic floor muscle weakness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic pain			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic prolapse			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postmenopausal haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectocele			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Uterine polyp			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vaginal polyp			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine prolapse			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vaginal fistula			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vaginal prolapse			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vaginal haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vulval leukoplakia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vulvar dysplasia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vulvovaginal pruritus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervical leukoplakia			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Genital prolapse			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute respiratory failure			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Aspiration			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asthma			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Asthmatic crisis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchiectasis			

subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Atelectasis				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bronchitis chronic				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic obstructive pulmonary disease				
subjects affected / exposed	5 / 2309 (0.22%)			
occurrences causally related to treatment / all	0 / 6			
deaths causally related to treatment / all	0 / 1			
Bronchospasm				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic respiratory disease				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dyspnoea				
subjects affected / exposed	3 / 2309 (0.13%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Cough				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dyspnoea exertional				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Emphysema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eosinophilic pneumonia chronic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epiglottic cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemoptysis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemothorax			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hydrothorax			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoxia			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Interstitial lung disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Laryngeal dysplasia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Laryngeal granuloma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung consolidation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Laryngeal polyp			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung disorder			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Mediastinal cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nasal polyps			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nasal septum deviation				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Obstructive airways disorder				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophagobronchial fistula				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pharyngeal pouch				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pickwickian syndrome				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleural effusion				
subjects affected / exposed	3 / 2309 (0.13%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Pleurisy				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleuritic pain				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia aspiration			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pneumonitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumothorax			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary arteriopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary fibrosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary hypertension			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary mass			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary oedema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary ossification			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary thrombosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory arrest			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory distress			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Respiratory tract inflammation			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinus polyp			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinus polyp degeneration			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sleep apnoea syndrome			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Throat irritation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tracheal stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vocal cord disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vocal cord polyp			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Alcohol abuse			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Alcohol withdrawal syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anxiety			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anxiety disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anxiety disorder due to a general medical condition			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bipolar disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Completed suicide			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Compulsive hoarding			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Confusional state			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Delirium				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Depression				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dysphemia				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Major depression				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dysthymic disorder				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mental disorder				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mood disorder due to a general medical condition				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Panic attack				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychogenic pain disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychotic disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychogenic seizure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood calcium decreased			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood cortisol increased			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood creatinine increased				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood parathyroid hormone increased				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood pressure increased				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood urea increased				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Coagulation time prolonged				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Electrocardiogram QT prolonged				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Electrocardiogram abnormal				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Grip strength decreased				

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemoglobin decreased				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Heart rate irregular				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
International normalised ratio decreased				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Investigation				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myocardial necrosis marker increased				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Occult blood positive				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Residual urine volume increased				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Weight decreased				

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Abdominal wound dehiscence			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acetabulum fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anastomotic leak			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Animal bite			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ankle fracture			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Aortic injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arterial injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arterial restenosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthropod bite			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atypical femur fracture			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Back injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bone contusion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bone fissure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac valve rupture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervical vertebral fracture			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Chillblains			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clavicle fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Comminuted fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Compression fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Concussion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Contusion			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Craniocerebral injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Excoriation			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Drug dispensing error				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Extradural haematoma				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Face injury				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Facial bones fracture				
subjects affected / exposed	2 / 2309 (0.09%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Fall				
subjects affected / exposed	2 / 2309 (0.09%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Femoral neck fracture				
subjects affected / exposed	9 / 2309 (0.39%)			
occurrences causally related to treatment / all	0 / 9			
deaths causally related to treatment / all	0 / 0			
Femur fracture				
subjects affected / exposed	4 / 2309 (0.17%)			
occurrences causally related to treatment / all	2 / 5			
deaths causally related to treatment / all	0 / 0			
Fibula fracture				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Foot fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Forearm fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fractured ischium			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fracture displacement			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fractured sacrum			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gun shot wound			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hand fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Head injury			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Heat illness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Heat exhaustion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Heat stroke			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hip fracture			
subjects affected / exposed	6 / 2309 (0.26%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Humerus fracture			
subjects affected / exposed	7 / 2309 (0.30%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Incisional hernia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Jaw fracture			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint dislocation			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Joint injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Laceration			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ligament rupture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Limb crushing injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ligament sprain			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Limb injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Limb traumatic amputation			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lower limb fracture			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lumbar vertebral fracture			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Meniscus injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mouth injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple injuries			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Muscle injury			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Muscle rupture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscle strain			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nerve root injury lumbar			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Patella fracture			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pelvic fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Perineal injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural complication			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural discomfort			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural fistula			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural haematoma			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural inflammation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural swelling			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post procedural oedema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post-traumatic neck syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative adhesion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative hernia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative ileus			

subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Postoperative respiratory failure				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Procedural complication				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Procedural haemorrhage				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Procedural nausea				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Procedural pain				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pubis fracture				
subjects affected / exposed	2 / 2309 (0.09%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pulmonary contusion				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Radius fracture				

subjects affected / exposed	6 / 2309 (0.26%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Rib fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Road traffic accident			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Scapula fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Scar			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin abrasion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin wound			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skull fracture			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skull fractured base			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Soft tissue injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal column injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal compression fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal cord injury cervical			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal fracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Splenic rupture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sternal fracture			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sternal injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subcutaneous haematoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subdural haematoma			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Subdural haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Synovial rupture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tendon injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tendon rupture			

subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Thoracic vertebral fracture				
subjects affected / exposed	2 / 2309 (0.09%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Thermal burn				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tibia fracture				
subjects affected / exposed	3 / 2309 (0.13%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Toxicity to various agents				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Traumatic haemorrhage				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Traumatic haemothorax				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Traumatic intracranial haemorrhage				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Traumatic shock				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ulna fracture			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Ulnar nerve injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper limb fracture			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular injury			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular pseudoaneurysm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound dehiscence			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound haemorrhage			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wrist fracture			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Atrial septal defect			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital bronchiectasis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital cystic kidney disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertrophic cardiomyopathy			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Exomphalos			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thyroglossal cyst			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			

Acute left ventricular failure subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute myocardial infarction subjects affected / exposed	9 / 2309 (0.39%)			
occurrences causally related to treatment / all	0 / 9			
deaths causally related to treatment / all	0 / 4			
Adams-Stokes syndrome subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Angina pectoris subjects affected / exposed	2 / 2309 (0.09%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Angina unstable subjects affected / exposed	4 / 2309 (0.17%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Aortic valve disease subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Aortic valve incompetence subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Aortic valve stenosis subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arrhythmia				

subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Arrhythmia supraventricular				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arteriosclerosis coronary artery				
subjects affected / exposed	3 / 2309 (0.13%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Atrial fibrillation				
subjects affected / exposed	10 / 2309 (0.43%)			
occurrences causally related to treatment / all	0 / 10			
deaths causally related to treatment / all	0 / 0			
Atrial tachycardia				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrioventricular block				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrioventricular block complete				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrial flutter				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrioventricular block first degree				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrioventricular block second degree			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrioventricular dissociation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bradyarrhythmia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bradycardia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bundle branch block bilateral			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bundle branch block left			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bundle branch block right			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute coronary syndrome			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac arrest			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure			
subjects affected / exposed	5 / 2309 (0.22%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 1		
Cardiac failure acute			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac failure chronic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Cardiac tamponade			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac valve disease			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac ventricular thrombosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardio-respiratory arrest			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiogenic shock			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiomyopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiopulmonary failure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiovascular disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiovascular insufficiency			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congestive cardiomyopathy			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery disease			
subjects affected / exposed	6 / 2309 (0.26%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 1		
Cor pulmonale acute			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery insufficiency			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery occlusion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery perforation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cytotoxic cardiomyopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Extrasystoles			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Heart valve incompetence			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertensive cardiomyopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Left ventricular failure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Microvascular coronary artery disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mitral valve disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mitral valve incompetence			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Mitral valve stenosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	5 / 2309 (0.22%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Myocardial ischaemia			
subjects affected / exposed	6 / 2309 (0.26%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 1		
Myocarditis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Palpitations			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericardial effusion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericardial haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postinfarction angina			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prinzmetal angina			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Right ventricular failure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinoatrial block			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinus bradycardia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericarditis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinus node dysfunction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stress cardiomyopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Supraventricular extrasystoles			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Supraventricular tachycardia			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tachyarrhythmia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tachycardia paroxysmal			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tricuspid valve incompetence			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular arrhythmia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular dysfunction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular extrasystoles			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular fibrillation			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular tachycardia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Amnesia			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Amyotrophic lateral sclerosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Apallic syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aphasia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ataxia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Balance disorder			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Basal ganglia haemorrhage			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Basal ganglia infarction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Brain injury			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Brain oedema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Brain stem infarction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Brain stem stroke			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid arteriosclerosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery aneurysm			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery occlusion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery thrombosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid sinus syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carpal tunnel syndrome			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cerebellar ischaemia			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebellar infarction			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral arteriosclerosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral artery embolism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral circulatory failure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral haematoma			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral haemorrhage			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 2		
Cerebral infarction			
subjects affected / exposed	5 / 2309 (0.22%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Cerebral ischaemia			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral thrombosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral venous thrombosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident			
subjects affected / exposed	4 / 2309 (0.17%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Cerebrovascular disorder			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular insufficiency			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervical myelopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervical radiculopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cognitive disorder			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Coma			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Complex partial seizures			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cranial nerve disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dementia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dementia Alzheimer's type			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Depressed level of consciousness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic neuropathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dizziness			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Dysarthria			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyslalia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Embolic cerebral infarction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Encephalopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epilepsy			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Frontotemporal dementia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Guillain-Barre syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhage intracranial			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Haemorrhagic stroke			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Headache			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hemiparesis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hemiplegia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic encephalopathy			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hydrocephalus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertensive encephalopathy			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypertonia			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemic coma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemic unconsciousness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotonia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
IVth nerve paralysis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
IIIrd nerve paralysis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intracranial aneurysm			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intracranial haematoma			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intracranial venous sinus thrombosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic cerebral infarction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic neuropathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	7 / 2309 (0.30%)		
occurrences causally related to treatment / all	1 / 7		
deaths causally related to treatment / all	0 / 1		
Lacunar infarction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Loss of consciousness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lumbar radiculopathy			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Memory impairment			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningorrhagia			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolic encephalopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Morton's neuralgia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Migraine			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Motor neurone disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myasthenia gravis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nerve root compression			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nerve compression			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neuritis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neuropathy peripheral			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Paraesthesia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Normal pressure hydrocephalus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Paraparesis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Parkinson's disease			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Parkinsonism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral nerve lesion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Partial seizures			

subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Peripheral sensorimotor neuropathy				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Polyneuropathy				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post herpetic neuralgia				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Presyncope				
subjects affected / exposed	3 / 2309 (0.13%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Radiculopathy				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Radicular syndrome				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ruptured cerebral aneurysm				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sciatica				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sedation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Seizure			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Senile dementia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sensory disturbance			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Slow speech			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal cord compression			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal cord haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Status epilepticus			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	4 / 2309 (0.17%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Thalamus haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombotic stroke			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Transient global amnesia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Trigeminal neuralgia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
VIIth nerve paralysis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular dementia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular encephalopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertebral artery stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
White matter lesion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Anaemia megaloblastic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaemia vitamin B12 deficiency			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aplastic anaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coagulopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Autoimmune haemolytic anaemia			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic diathesis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypochromic anaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune thrombocytopenic purpura			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Iron deficiency anaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphadenitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphadenopathy			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Lymphadenopathy mediastinal			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Normochromic normocytic anaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancytopenia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Polycythaemia			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pernicious anaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Deafness neurosensory			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ear haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
External ear disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inner ear disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meniere's disease			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neurosensory hypoacusis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sudden hearing loss			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Otosclerosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tinnitus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertigo			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tympanic membrane perforation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertigo positional			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Age-related macular degeneration			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Amaurosis fugax			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angle closure glaucoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blindness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blindness unilateral			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cataract nuclear			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cataract			
subjects affected / exposed	9 / 2309 (0.39%)		
occurrences causally related to treatment / all	0 / 13		
deaths causally related to treatment / all	0 / 0		
Chalazion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Choroiditis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Conjunctival haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Corneal opacity			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cystoid macular oedema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dacryostenosis acquired			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diplopia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Entropion			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Excessive eye blinking			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eyelid ptosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glaucoma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Iritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Keratitis interstitial			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Keratitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Keratopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lacrimal disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lens disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Macular degeneration			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Macular fibrosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Macular hole			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Maculopathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myopia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neovascular age-related macular degeneration			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Optic atrophy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Optic ischaemic neuropathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Posterior capsule opacification			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Retinal artery embolism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal degeneration			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal detachment			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal dystrophy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal haemorrhage			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Retinal vein occlusion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal vein thrombosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinopathy			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Trichiasis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ulcerative keratitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vision blurred			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Visual acuity reduced			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Visual impairment			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vitreous haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Corneal scar			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Flat anterior chamber of eye			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Open angle glaucoma			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Ciliary body disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal hernia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal distension			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal hernia obstructive			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain lower			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal fistula			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal fissure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal inflammation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ascites			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Barrett's oesophagus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic gastritis			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Change of bowel habit			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Colitis ischaemic			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Colitis ulcerative			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Colitis microscopic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dental caries			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Crohn's disease			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Diverticular perforation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diverticulum			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Diverticulitis intestinal haemorrhagic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diverticulum intestinal			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diverticulum intestinal haemorrhagic			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diverticulum oesophageal			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dolichocolon acquired			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenal perforation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenal ulcer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenal ulcer perforation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dysbacteriosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspepsia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dysphagia			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enteritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterocoele			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterocolitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterocutaneous fistula			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterovesical fistula			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Erosive oesophagitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Faecal incontinence			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Faecaloma			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femoral hernia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal mass			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal prolapse			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femoral hernia incarcerated			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Functional gastrointestinal disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Food poisoning			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric antral vascular ectasia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric haemorrhage			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Gastric ulcer			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric ulcer perforation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastritis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastritis erosive			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroduodenitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal angiodysplasia			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal inflammation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal motility disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal necrosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal obstruction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal ulcer haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haematemesis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematochezia			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhoids			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal ulcer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhoids thrombosed			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hernial eventration			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hiatus hernia			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ileus			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ileus paralytic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal ischaemia			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Intestinal mass			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal perforation			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal prolapse			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal polyp			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intussusception			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Irritable bowel syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischiorectal hernia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestine perforation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestine polyp			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Lower gastrointestinal haemorrhage			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lumbar hernia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mallory-Weiss syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mechanical ileus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Melaena			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Mesenteric artery embolism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mouth cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mouth ulceration			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Obstruction gastric			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal achalasia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal fistula			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal pain			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal hypomotility			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophagitis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophagitis ulcerative			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oral pain			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic mass			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic pseudocyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis acute			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pancreatitis chronic			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis necrotising			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peptic ulcer			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peptic ulcer perforation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peptic ulcer haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pharyngo-oesophageal diverticulum			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal haemorrhage			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Rectal polyp			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal prolapse			

subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Salivary gland calculus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Splenic artery aneurysm			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stomach mass			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombosis mesenteric vessel			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subileus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toothache			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Umbilical hernia			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Retroperitoneal haematoma			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Volvulus			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Varices oesophageal			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric polyps			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bile duct stenosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Biliary colic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bile duct stone			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Biliary fistula			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholangitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholangitis acute			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Cholecystitis chronic			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Chronic hepatitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gallbladder disorder			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gallbladder polyp			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic cirrhosis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hepatic cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic failure			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hepatic steatosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis cholestatic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatorenal failure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Jaundice			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Jaundice cholestatic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Liver disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-alcoholic steatohepatitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post cholecystectomy syndrome			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hydrocholecystitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Perforation bile duct			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Portal vein thrombosis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute generalised exanthematous pustulosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angioedema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrophoderma of Pasini and Pierini			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blister			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Decubitus ulcer			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dermal cyst			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dermatitis allergic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dermatitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dermatitis contact			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dermatitis atopic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dermatomyositis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic foot			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eczema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eczema asteatotic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Erythema multiforme			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Erythema nodosum			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hand dermatitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Henoch-Schonlein purpura			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperkeratosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypersensitivity vasculitis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ingrowing nail			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lentigo			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukoplakia			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lichen sclerosus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neurodermatitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pemphigoid			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pemphigus			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pruritus generalised			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psoriasis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyoderma gangrenosum			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash erythematous			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash generalised			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin ulcer			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Skin wrinkling			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urticaria			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Acute prerenal failure			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Azotaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder diverticulum			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder irritation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder perforation			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder prolapse			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Calculus bladder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Calculus ureteric			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Calculus urethral			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Calculus urinary			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic kidney disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glomerulonephritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cystitis haemorrhagic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glomerulonephritis membranous			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Glomerulonephritis rapidly progressive				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haematuria				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hydronephrosis				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertonic bladder				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nephrotic syndrome				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Nephrolithiasis				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Oliguria				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pollakiuria				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal artery stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal colic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal impairment			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal mass			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal tubular disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Scleroderma renal crisis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stress urinary incontinence			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ureteric stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral caruncle			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral polyp			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral stenosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary bladder polyp			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary incontinence			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary retention			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adrenal haemorrhage			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Autoimmune thyroiditis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Goitre			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperadrenalism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperparathyroidism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperparathyroidism primary			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypothyroidism			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperthyroidism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Primary hypothyroidism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Secondary hyperthyroidism			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thyroid cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thyroiditis subacute			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thyroid mass			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			

Arthralgia				
subjects affected / exposed	3 / 2309 (0.13%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Arthritis				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arthritis reactive				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atlantoaxial instability				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Axillary mass				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Back pain				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bone loss				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bone pain				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bursitis				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chondropathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Connective tissue disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dupuytren's contracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Costochondritis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eosinophilic fasciitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Facet joint syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Foot deformity			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fracture delayed union			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fracture malunion			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fracture pain			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemarthrosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc degeneration			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc protrusion			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc space narrowing			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Jaw cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint adhesion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint contracture			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint effusion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint stiffness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint range of motion decreased			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint swelling			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Knee deformity			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lumbar spinal stenosis			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Mobility decreased			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Monarthrititis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Morphoea			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscle spasms			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscular weakness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal chest pain			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal pain			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myalgia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nodal osteoarthritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			
subjects affected / exposed	12 / 2309 (0.52%)		
occurrences causally related to treatment / all	0 / 13		
deaths causally related to treatment / all	0 / 0		
Osteochondritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteochondrosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteonecrosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteosclerosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain in extremity			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Periarthritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Periostitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Plantar fasciitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Polymyalgia rheumatica			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Rotator cuff syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rheumatoid arthritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Scleroderma			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Scoliosis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sjogren's syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Soft tissue necrosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal column stenosis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal osteoarthritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal pain			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spondylitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spondyloarthropathy			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spondylolisthesis			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Synovial cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Synovitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Systemic lupus erythematosus			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tendonitis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tenosynovitis stenosaurs			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Trigger finger			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ulnocarpal abutment syndrome			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abdominal abscess			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal sepsis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal wall abscess			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abscess			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abscess limb			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abscess neck			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute sinusitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Amoebic colitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis			

subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Appendicitis perforated			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthritis bacterial			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthritis infective			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Beta haemolytic streptococcal infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bronchopneumonia			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Burn infection				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Campylobacter infection				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Carbuncle				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	3 / 2309 (0.13%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Catheter site infection				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Central nervous system viral infection				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chlamydial infection				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cholecystitis infective				

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic sinusitis				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile infection				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile colitis				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cutaneous tuberculosis				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cytomegalovirus gastrointestinal infection				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cytomegalovirus infection				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dacryocystitis				

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dengue fever			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dental fistula			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device related infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device related sepsis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic gangrene			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea infectious			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diverticulitis			
subjects affected / exposed	4 / 2309 (0.17%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Dysentery			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endophthalmitis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Enteritis infectious			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterobacter pneumonia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Erysipelas			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Erythema migrans			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Escherichia urinary tract infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gallbladder empyema			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gangrene			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastritis viral			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis bacterial			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis clostridial			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis salmonella			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis viral			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal infection			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal viral infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocarditis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Endometritis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Epstein-Barr virus infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Extradural abscess			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diverticulitis intestinal haemorrhagic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis norovirus			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Genital candidiasis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Graft infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Groin abscess			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematoma infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Helicobacter gastritis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis A			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Helicobacter infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis E			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes simplex encephalitis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes zoster			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes zoster infection neurological			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incision site infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Implant site infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infected bites			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infected dermal cyst			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infected varicose vein			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection			

subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infective exacerbation of bronchiectasis				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infective exacerbation of chronic obstructive airways disease				
subjects affected / exposed	1 / 2309 (0.04%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral discitis				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal fistula infection				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Keratitis bacterial				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Labyrinthitis				
subjects affected / exposed	0 / 2309 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Klebsiella bacteraemia				

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Laryngitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Liver abscess			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lobar pneumonia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Localised infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lower respiratory tract infection			
subjects affected / exposed	2 / 2309 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lyme disease			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung infection			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malaria			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mediastinitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningitis bacterial			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutropenic sepsis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neurosyphilis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal candidiasis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oral candidiasis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteomyelitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Otitis media			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatic abscess			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Parotitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic sepsis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Periorbital cellulitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peritonitis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peritonsillar abscess			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peritonsillitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pharyngitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pharyngotonsillitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	19 / 2309 (0.82%)		
occurrences causally related to treatment / all	0 / 19		
deaths causally related to treatment / all	0 / 3		
Pneumonia bacterial			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia necrotising			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia pneumococcal			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia viral			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural infection			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Postoperative wound infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pseudomembranous colitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pseudomonal bacteraemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary echinococcosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary sepsis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary tuberculosis			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelocystitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis acute			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis chronic			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyometra			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyonephrosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal abscess			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Salmonellosis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	5 / 2309 (0.22%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 3		
Septic shock			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Sialoadenitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinobronchitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinusitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin infection			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal sepsis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal skin infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stoma site abscess			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subcutaneous abscess			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subdiaphragmatic abscess			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tick-borne fever			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tonsillitis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tooth infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tracheitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	9 / 2309 (0.39%)		
occurrences causally related to treatment / all	0 / 11		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection bacterial			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection pseudomonal			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vestibular neuronitis			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral infection			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Viral labyrinthitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound sepsis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound infection staphylococcal			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vaginal abscess			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchitis bacterial			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bacterial infection			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Decreased appetite			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diabetes mellitus			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diabetic ketoacidosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic metabolic decompensation			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Electrolyte imbalance			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gout			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypercalcaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperosmolar state			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			

subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	3 / 2309 (0.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hypophagia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypovolaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ketoacidosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malnutrition			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolic acidosis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolic disorder			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Type 1 diabetes mellitus			

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 2309 (0.04%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Base Study + First Extension: Odanacatib 50 mg OW	Base Study + First Extension: Placebo	Second Extension: Odanacatib 50 mg OW
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5659 / 8043 (70.36%)	5624 / 8028 (70.05%)	311 / 3144 (9.89%)
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	476 / 8043 (5.92%)	499 / 8028 (6.22%)	0 / 3144 (0.00%)
occurrences (all)	761	736	0
Contusion			
subjects affected / exposed	386 / 8043 (4.80%)	422 / 8028 (5.26%)	0 / 3144 (0.00%)
occurrences (all)	500	568	0
Vascular disorders			
Hypertension			
subjects affected / exposed	1104 / 8043 (13.73%)	1084 / 8028 (13.50%)	0 / 3144 (0.00%)
occurrences (all)	1263	1278	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	492 / 8043 (6.12%)	483 / 8028 (6.02%)	0 / 3144 (0.00%)
occurrences (all)	574	565	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	477 / 8043 (5.93%)	500 / 8028 (6.23%)	0 / 3144 (0.00%)
occurrences (all)	552	583	0
Eye disorders			

Cataract subjects affected / exposed occurrences (all)	488 / 8043 (6.07%) 638	492 / 8028 (6.13%) 652	0 / 3144 (0.00%) 0
Gastrointestinal disorders Constipation subjects affected / exposed occurrences (all)	492 / 8043 (6.12%) 547	504 / 8028 (6.28%) 552	0 / 3144 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	589 / 8043 (7.32%) 726	504 / 8028 (6.28%) 608	0 / 3144 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	471 / 8043 (5.86%) 553	466 / 8028 (5.80%) 544	0 / 3144 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1221 / 8043 (15.18%) 1588	1151 / 8028 (14.34%) 1533	0 / 3144 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	1194 / 8043 (14.85%) 1473	1136 / 8028 (14.15%) 1394	0 / 3144 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	518 / 8043 (6.44%) 589	461 / 8028 (5.74%) 537	0 / 3144 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	751 / 8043 (9.34%) 923	671 / 8028 (8.36%) 797	0 / 3144 (0.00%) 0
Osteoarthritis subjects affected / exposed occurrences (all)	785 / 8043 (9.76%) 980	741 / 8028 (9.23%) 910	0 / 3144 (0.00%) 0
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	450 / 8043 (5.59%) 591	459 / 8028 (5.72%) 611	0 / 3144 (0.00%) 0
Influenza			

subjects affected / exposed	495 / 8043 (6.15%)	443 / 8028 (5.52%)	0 / 3144 (0.00%)
occurrences (all)	610	564	0
Nasopharyngitis			
subjects affected / exposed	957 / 8043 (11.90%)	938 / 8028 (11.68%)	0 / 3144 (0.00%)
occurrences (all)	1396	1365	0
Upper respiratory tract infection			
subjects affected / exposed	644 / 8043 (8.01%)	596 / 8028 (7.42%)	0 / 3144 (0.00%)
occurrences (all)	962	913	0
Urinary tract infection			
subjects affected / exposed	1724 / 8043 (21.43%)	1699 / 8028 (21.16%)	311 / 3144 (9.89%)
occurrences (all)	2911	2821	393

Non-serious adverse events	Second Extension: Odanacatib 50 mg OW (Placebo)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	209 / 2309 (9.05%)		
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences (all)	0		
Contusion			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences (all)	0		
Eye disorders			

Cataract subjects affected / exposed occurrences (all)	0 / 2309 (0.00%) 0		
Gastrointestinal disorders Constipation subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all)	0 / 2309 (0.00%) 0 0 / 2309 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 2309 (0.00%) 0		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) Back pain subjects affected / exposed occurrences (all) Musculoskeletal pain subjects affected / exposed occurrences (all) Pain in extremity subjects affected / exposed occurrences (all) Osteoarthritis subjects affected / exposed occurrences (all)	0 / 2309 (0.00%) 0 0 / 2309 (0.00%) 0 0 / 2309 (0.00%) 0 0 / 2309 (0.00%) 0 0 / 2309 (0.00%) 0		
Infections and infestations Bronchitis subjects affected / exposed occurrences (all) Influenza	0 / 2309 (0.00%) 0		

subjects affected / exposed	0 / 2309 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 2309 (0.00%)		
occurrences (all)	0		
Urinary tract infection			
subjects affected / exposed	209 / 2309 (9.05%)		
occurrences (all)	271		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
03 August 2008	Amendment 1; applicable to MK-0822-018 Base Study.
06 August 2009	Amendment 1: applicable to MK-0822-032 Imaging Substudy-Base
14 September 2009	Amendment 1: applicable to MK-0822-035 Imaging Substudy
27 April 2010	Amendment 2: applicable to MK-0822-018 Base Study.
25 April 2011	Amendment 10: defined Extension 1 to MK-0822-018 Base Study.
11 October 2011	Amendment 3: applicable to MK-0822-018 Base Study.
11 October 2011	Amendment 10: defined Extension to MK-0822-032 Imaging Substudy-Base.
07 March 2012	Amendment 4: applicable to MK-0822-018 Base Study.
08 January 2013	Amendment 5: applicable to MK-0822-018 Base Study.
09 January 2013	Amendment 20: defined Extension 2 to MK-0822-018 Base + Extension 1 Study.
24 June 2013	Amendment 6: applicable to MK-0822-018 Base Study.
22 November 2013	Amendment 11: applicable to MK-0822-032 Imaging Substudy-Extension.
22 July 2014	Amendment 21: applicable to MK-0822-018 Extension 2 Study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported